

Approved



South Africa
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,638,119		1,638,119	1,276,709	2,914,828
USAID		180,419,029	0	180,419,029	47,622,566	228,041,595
DOD		0		0	817,796	817,796
PC		1,750,000		1,750,000	625,000	2,375,000
HHS/CDC	3,450,000	92,594,651		96,044,651	71,051,532	167,096,183
HHS/HRSA		6,854,056		6,854,056	225,000	7,079,056
State/AF		1,675,542		1,675,542	0	1,675,542
Total	3,450,000	284,931,397	0	288,381,397	121,618,603	410,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC	0	0	1,926,901				15,848,975	0	17,775,876
HBHC	0		11,262,365	60,000	0	223,500	24,990,306	0	36,536,171
HKID	18,682		3,399,623		151,371	1,079,542	21,761,265	0	26,410,483
HLAB	0		520,608					0	520,608
HMBL	0							0	0
HMIN	0							0	0
HTXD	0	0					35,820	0	35,820
HTXS	0	0	31,742,444	200,000			61,274,138	0	93,216,582
HVAB	0	0	1,755,846		0		839,444	0	2,595,290
HVCT	0	0	13,000,685	0			11,221,479	0	24,222,164

Approved



HVMS	1,603,091	0	3,450,000		1,518,629		8,006,635	0	14,578,355
HVOP	0	0	511,321	400,000	80,000	223,500	2,863,315	0	4,078,136
HVSI	16,346		3,348,354				1,039,917	0	4,404,617
HVTB	0	0	11,699,565	60,000			11,885,982	0	23,645,547
IDUP	0		70,000					0	70,000
MTCT	0		3,757,714	40,000			8,504,869	0	12,302,583
OHSS	0		3,129,452	6,054,056		149,000	2,914,745	0	12,247,253
PDCS	0		2,746,515	20,000			5,266,583	0	8,033,098
PDTX	0		3,723,258	20,000			3,965,556	0	7,708,814
	1,638,119	0	96,044,651	6,854,056	1,750,000	1,675,542	180,419,029	0	288,381,397



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	36,338,281	0
HKID	25,986,620	0
HVTB	23,469,169	0
PDCS	7,933,006	0
Total Technical Area Planned Funding:	93,727,076	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	520,608	0
HVSI	3,848,354	0
OHSS	11,817,568	0
Total Technical Area Planned Funding:	16,186,530	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	17,558,116	0
HVAB	2,396,452	0
HVCT	24,097,758	0
HVOP	3,782,335	0
IDUP	70,000	0
MTCT	12,154,667	0
Total Technical Area Planned Funding:	60,059,328	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	0	0
HTXS	92,848,723	0
PDTX	7,576,668	0
Total Technical Area Planned Funding:	100,425,391	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,648
	Number of new ANC and L&D clients	136,110
	By: Known positives at entry	48,964
	By: Number of new positives identified	61,872
	Sum of Positives Status disaggregates	110,836
	Required only for DREAMS Countries - By Number of new positives: <15	1
	Required only for DREAMS Countries - By Number of new positives: 15-19	240
	Required only for DREAMS Countries - By Number of new positives: 20-24	756
	Required only for DREAMS Countries - By Number of known positives: <15	2
	Required only for DREAMS Countries - By Number of known	936



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	3,454
	Required only for DREAMS Countries - Denominator: <15	9
	Required only for DREAMS Countries - Denominator: <15-19	3,190
	Required only for DREAMS Countries - Denominator: 20-24	11,579
	Required only for DREAMS Countries - Denominator: 25-49	15,987
	Required only for DREAMS Countries - Denominator: 50+	0
	Required only for DREAMS Countries - By Number of known positives: 25-49	4,744
	Required only for DREAMS Countries - By Number of known positives: 50+	0
	Required only for DREAMS Countries - By Number of new positives: 25-49	1,857
	Required only for DREAMS Countries - By Number of new positives: 50+	0
	By Age (DREAMS SNU's ONLY): <15	211
	By Age (DREAMS SNU's ONLY): 15-19	3,046
	By Age (DREAMS SNU's ONLY): 20-24	11,180
	By Age (DREAMS SNU's ONLY): 25-49	17,780



	By Age (DREAMS SNU's ONLY): 50+	0
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	586,798
	Number of new ANC and L&D clients	600,127
	By: Known positives at entry	138,609
	By: Number of new positives identified	142,225
	Sum of Positives Status disaggregates	280,834
	Required only for DREAMS countries - By known positives: <15	98
	Required only for DREAMS countries - By known positives: 15-19	4,031
	Required only for DREAMS countries - By known positives: 20-24	15,096
	Required only for DREAMS countries - By new positives: <15	143
	Required only for DREAMS countries - By new positives: 15-19	3,587
	Required only for DREAMS countries - By new positives: 20-24	13,054
	Required only for DREAMS countries - Denominator: <15	80



	Required only for DREAMS countries - Denominator: 15-19	11,684
	Required only for DREAMS countries - Denominator: 20-24	41,524
	Required only for DREAMS countries - Denominator: 25-49	89,795
	Required only for DREAMS countries - Denominator: 50+	893
	Required only for DREAMS countries - By known positives: 25-49	36,327
	Required only for DREAMS countries - By known positives: 50+	296
	Required only for DREAMS countries - By new positives: 25-49	39,489
	Required only for DREAMS countries - By new positives: 50+	545
	By Age (DREAMS SNU's ONLY): <15	733
	By Age (DREAMS SNU's ONLY): 15-19	15,232
	By Age (DREAMS SNU's ONLY): 20-24	55,868
	By Age (DREAMS SNU's ONLY): 25-49	140,309
	By Age (DREAMS SNU's ONLY): 50+	1,522
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,648
	New on ART	13,281
	Already on ART at beginning of current pregnancy	9,841
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	586,798
	New on ART	87,903
	Already on ART at beginning of current pregnancy	44,464
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	428,486
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	34,450
	By Age: 15-19	119,644
	By Age: 20-24	104,995
	By Age: 25-29	144,407
	By Age: 30-49	15,450
	By Age: 50+	8,260



	Sum of age disaggregates (Prior to FY15)	267,349
	Sum of age disaggregates (FY15-Current)	427,206
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	370,192
	By circumcision technique: Device-based VMMC	57,595
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	1,501



	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	1,501
	Female 25-49	
	Female 50+	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,616,408
	Total number of people in the target population	9,922,201
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	



	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	102,915
	Aggregated Age/sex: 15+ Male	740,858
	Aggregated Age/sex: <15 Female	157,343
	Aggregated Age/sex: 15+ Female	616,255
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	53,933



	Total number of people in the target population	1,441,286
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	3,938
	Aggregated Age/sex: 15+ Male	16,185
	Aggregated Age/sex: <15 Female	4,792
	Aggregated Age/sex: 15+ Female	78,486
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	140,017
	Total estimated number of key population in the catchment area	371,317
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of	



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	28,082
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	40,520



	required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,191
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	125
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	70,099
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	8,960
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	149,026
	By key population type:	



	Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	79,458
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	4,766
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	528
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	128,677
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	



	By New Client Status: RReturning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,963,401
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	15,787
	Age/sex: 15-19 Male	51,205
	Age/sex: 20-24 Male	148,146
	Age/sex: 25-49 Male	255,665
	Age/sex: 50+ Male	39,879
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	38,736
	Age/sex: 15-19 Female	86,368
	Age/sex: 20-24 Female	171,681
	Age/sex: 25-49 Female	222,451
	Age/sex: 50+ Female	41,439
	Test Result by Age and Sex: Positive: 10-14 Male	2,035
	Test Result by Age and Sex: Positive: 15-19 Male	6,770
	Test Result by Age and Sex: Positive: 20-24 Male	19,445
	Test Result by Age and Sex: Positive: 25-49 Male	33,246
	Test Result by Age and Sex: Positive: 50+ Male	4,783
	Test Result by Age and Sex: Positive: 10-14 Female	4,576
	Test Result by Age and Sex: Positive: 15-19 Female	10,947



Test Result by Age and Sex: Positive: 20-24 Female	25,150
Test Result by Age and Sex: Positive: 25-49 Female	33,175
Test Result by Age and Sex: Positive: 50+ Female	5,018
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	
Test Result by Age and Sex: Negative: 50+ Male	
Test Result by Age and Sex: Negative: 10-14 Female	
Test Result by Age and Sex: Negative: 15-19 Female	
Test Result by Age and Sex: Negative: 20-24 Female	
Test Result by Age and Sex: Negative: 25-49 Female	
Test Result by Age and Sex: Negative: 50+ Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	124,979
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,147,939
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	150,110
Aggregated Age/sex - USE WITH	1,351,850



	HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	13,010
	Test Result by Aggregated Age and Sex: Positive 15+ Male	143,420
	Test Result by Aggregated Age and Sex: Positive <15 Female	17,489
	Test Result by Aggregated Age and Sex: Positive 15+ Female	187,252
	Test Result by Age: Positive: <1	1,153
	Test Result by Age: Positive: 1-9	3,534
	Age/sex: <1	16,976
	Age/sex: 1-9	33,967
	Service Delivery Point (Community): Index testing	128,035
	Service Delivery Point (Community): Homebased testing	759,428
	Service Delivery Point (Community): Mobile testing	761,047
	Service Delivery Point (Community): Other	173,527
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	



	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	15,929
	Service Delivery Point (Facility): Outpatient	387,778
	Service Delivery Point (Facility): Pediatric	81,622
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	33,856
	Service Delivery Point (Facility): VCT	323,321
	Service Delivery Point (Facility): VMMC	26,252
	Service Delivery Point (Facility): PMTCT	255,435
	Service Delivery Point (Facility): TB Clinics	615
	Service Delivery Point (Facility): Index testing	1,003
	Service Delivery Point (Facility) by Age: <15 Inpatient	



	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	



	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,966,527
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	15,375
	Age/sex: 15-19 Male	27,415
	Age/sex: 20-24 Male	64,314
	Age/sex: 25-49 Male	186,624
	Age/sex: 50+ Male	36,035
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	16,282
	Age/sex: 15-19 Female	43,708
	Age/sex: 20-24 Female	108,817
	Age/sex: 25-49 Female	300,009
	Age/sex: 50+ Female	45,760
	Test Result by Age and Sex: Positive: 10-14 Male	2,783
	Test Result by Age and Sex: Positive: 15-19 Male	4,861
	Test Result by Age and Sex: Positive: 20-24 Male	11,283
	Test Result by Age and Sex: Positive: 25-49 Male	33,053
	Test Result by Age and Sex: Positive: 50+ Male	6,056
Test Result by Age and Sex: Positive: 10-14 Female	2,818	
Test Result by Age and Sex:	7,194	



	Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	19,854
	Test Result by Age and Sex: Positive: 25-49 Female	50,658
	Test Result by Age and Sex: Positive: 50+ Female	7,521
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	104,831
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,253,438
	Aggregated Age/sex - USE WITH	113,025



	HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,518,385
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	12,604
	Test Result by Aggregated Age and Sex: Positive 15+ Male	199,976
	Test Result by Aggregated Age and Sex: Positive <15 Female	14,034
	Test Result by Aggregated Age and Sex: Positive 15+ Female	254,037
	Test Result by Age: Positive: <1	983
	Test Result by Age: Positive: 1-9	6,094
	Age/sex: <1	13,202
	Age/sex: 1-9	34,590
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community)	



	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	182,087
	Service Delivery Point (Facility): Outpatient	378,920
	Service Delivery Point (Facility): Pediatric	129,864
	Service Delivery Point (Facility): Malnutrition facilities	30,901
	Service Delivery Point (Facility): Other PITC	424,124
	Service Delivery Point (Facility): VCT	1,145,616
	Service Delivery Point (Facility): VMMC	26,765
	Service Delivery Point (Facility): PMTCT	487,550
	Service Delivery Point (Facility): TB Clinics	68,950
	Service Delivery Point (Facility):	101,315



	Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	36,333
	Total number of registered new and relapsed TB cases, during the reporting period.	38,941
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,134
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14,837
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,288
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17,687
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total	



	number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		186,705
Total number of registered new and relapsed TB cases, during the		196,510



	reporting period.	
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,147
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73,522
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered	11,020



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	90,416
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	22,975
	Age/Sex: <10 Male	0
	Age/Sex: 10-14 Male	0
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	0
	Age/Sex: 25-49 Male	0
	Age/Sex: 50+ Male	0
	Age/Sex: <10 Female	0
	Age/Sex: 10-14 Female	1,237
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	



	Age/Sex: 20-24 Female	10,017
	Age/Sex: 25-49 Female	0
	Age/Sex: 50+ Female	0
	Sum of Age/Sex Disaggregates	1,237
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,192
	By type of service: Sexual Violence (Post-Rape Care)	19,485
	By PEP service provision (related to sexual violence services provided)	10,879
	Age/Sex: 15-19 Female	10,006
	Age/Sex: 15-19 male	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	304,480
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	16,824
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	34,308
	Sum of Age/Sex disaggregates	51,132
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS	1,634



	countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,538
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	116
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS	4,397



	countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	10,741
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	



	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	15,359
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	9,155
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	247
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,331
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,327
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	896
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	9,979
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	9,470
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,046
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	



	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	83,211
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	156,864
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	360,041
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	24,760
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
Age/Sex: 18+ Female	46,214	



	Sum of Age/Sex disaggregates	70,974
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female	



	25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	



	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas	



	Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas	
	Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male	



	18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during	n/a



	TB treatment	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19,402
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	22,347
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator:	



	<p>The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on</p>	



	ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,731
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,203
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,215



	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,598
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	103,365
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	113,397
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during</p>	



	the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7,808
	Aggregated Age/Sex: Male 15+	39,737



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,874
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49,388
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	877,424
	Screened for TB by Age/Sex:<15 Male	16,067
	Screened for TB by Age/Sex: 15+ Male	163,043
	Screened for TB by Age/Sex:<15 Female	13,453
	Screened for TB by Age/Sex: 15+ Female	188,885



	Screen Result: Screened Positive for TB	21,186
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	19,523
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	927
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9,077
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	10,243
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,860,979
	Screened for TB by Age/Sex: <15 Male	156,270
	Screened for TB by Age/Sex: 15+ Male	1,322,984
	Screened for TB by Age/Sex: <15 Female	153,568
	Screened for TB by Age/Sex: 15+ Female	1,658,195
	Screen Results: Screened Positive for TB	198,974
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	



	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	182,246
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	13,128
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	135,953
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	35,778
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	21,941
	By infants who received their first virologic HIV test between 2 and 12 months of age	758
	Sum of Infant Age disaggregates	22,699
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive	160



	virological test result within 2 months of birth	
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	24
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	122,499
	By infants who received their first virologic HIV test between 2 and 12 months of age	9,794
	Sum of Infant Age disaggregates	132,293
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive	1,328



	virological test result within 2 months of birth	
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	208
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	840,771
	Age/Sex: 15-19 Male	11,181
	Age/Sex: 15-19 Female	13,607
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	35,881
	Aggregated Age/Sex: 15+ Male	230,578
	Aggregated Age/Sex: <15 Female	47,926
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	326,783
	Sum of Aggregated Age/Sex <15	83,807
	Sum of Aggregated Age/Sex 15+	557,361
	Sum of Aggregated Age/Sex disaggregates	641,168
	Age/Sex: <1	4,672
Age/Sex: <1-9	5,974	



	Age/Sex: 10-14 Male	5,295
	Age/Sex: 10-14 Female	5,280
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	30,639
	Age/Sex: 25-49 Male	66,583
	Age/Sex: 50+ Male	24,864
	Age/Sex: 20-24 Female	40,000
	Age/Sex: 25-49 Female	105,024
	Age/Sex: 50+ Female	29,783
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	3,104,562
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	16,318
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	30,406
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	46,724
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	133,361
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	1,084,438
Aggregated Age/Sex: <15 Female	136,417	
Aggregated Age/Sex: 1-14 Female		



	Aggregated Age/Sex: 15+ Female	1,560,026
	Sum of Aggregated Age/Sex <15	269,778
	Sum of Aggregated Age/Sex 15+	2,644,464
	Sum of Aggregated Age/Sex disaggregates	2,914,242
	Age/Sex: <1	11,541
	Age/Sex: 1-9	26,326
	Age/Sex: 10-14 Male	13,363
	Age/Sex: 10-14 Female	13,355
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	47,156
	Age/Sex: 25-49 Male	233,155
	Age/Sex: 50+ Male	60,162
	Age/Sex: 20-24 Female	95,089
	Age/Sex: 25-49 Female	440,396
	Age/Sex: 50+ Female	68,186
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	303,365
	By Age/Sex: <1	1,163
	By Age/Sex: 1-9	1,239
	By Age/Sex: 10-14 Male	1,355
	By Age/Sex: 15-19 Male	2,933
	By Age/Sex: 20-24 Male	8,335
	By Age/Sex: 25-49 Male	18,000
	By Age/Sex: 50+ Male	6,571
	By Age/Sex: 10-14 Female	1,363
	By Age/Sex: 15-19 Female	3,783
	By Age/Sex: 20-24 Female	11,385
	By Age/Sex: 25-49 Female	29,530
	By Age/Sex: 50+ Female	7,940



	Sum of Age/Sex disaggregates	91,195
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	13,649
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	84,286
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	19,082
	Aggregated Grouping by Age/Sex: 15+ Female	125,652
	Sum of Aggregated Age/Sex disaggregates	242,669
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	663,896
	By Age/Sex: <1	
	By Age/Sex: 1-9	3,570
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	2,158
	By Age/Sex: 15-19 Male	3,266
	By Age/Sex: 20-24 Male	10,335



	By Age/Sex: 25-49 Male	48,629
	By Age/Sex: 50+ Male	11,531
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	2,192
	By Age/Sex: 15-19 Female	6,740
	By Age/Sex: 20-24 Female	23,044
	By Age/Sex: 25-49 Female	94,549
	By Age/Sex: 50+ Female	14,733
	Sum of Age/Sex disaggregates	217,177
	Aggregated Grouping by Age: <1	1,861
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	23,084
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	226,234
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	25,398
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	336,847
	Sum of Aggregated Age/Sex disaggregates	611,563
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of	n/a



	ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	687,728
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	765,214
	Numerator: Indication: Routine	446,203
	Numerator: Indication: Targeted	39,692
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	



	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	



	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	159,874
	Denominator: Indication: Targeted	8,780
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	



	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	



	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	37,093
	Numerator Aggregated Age/Sex: 15+ Male	254,976
	Numerator Aggregated Age/Sex: <15 Female	45,767



	Numerator Aggregated Age/Sex: 15+ Female	351,045
	Denominator Aggregated Age/Sex: <15 Male	13,326
	Denominator Aggregated Age/Sex: 15+ Male	86,885
	Denominator Aggregated Age/Sex: <15 Female	12,204
	Denominator Aggregated Age/Sex: 15+ Female	94,542
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,515,849
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,760,900
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication:	
	Numerator: Age/Sex by Indication:	



	1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication:	



	50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	1,362,528
	Numerator: Indication: Targeted	94,739
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	1,445,524



	Denominator: Indication: Targeted	105,142
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	117,326
	Numerator Aggregated Age/Sex: 15+ Male	949,539
	Numerator Aggregated Age/Sex: <15 Female	114,563
	Numerator Aggregated Age/Sex: 15+ Female	1,349,334
	Denominator Aggregated Age/Sex: <15 Male	121,801
	Denominator Aggregated Age/Sex: 15+ Male	943,062
	Denominator Aggregated Age/Sex: <15 Female	119,016
	Denominator Aggregated Age/Sex: 15+ Female	1,361,754
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	459,099
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	493,817



	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,473
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,500
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,141
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,442
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,734
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37,656
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,095
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,135
	Age/Sex: 15-19 Female (Numerator: Number of adults and	7,733



	children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,463
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55,485
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,775
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,851
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,164
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	608



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,036
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,417
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,992
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,112
	Age/Sex: 10-14 Female	598



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	807
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,644
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,976
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	9,365



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and	20,282



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125,667
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,652
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165,141
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,722
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61,030
	Aggregated Age/Sex: <15 Female (Denominator: Total number of	8,020



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>66,672</p>
<p>TX_RET_TA</p>	<p>TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy</p>	<p>n/a</p>
	<p>Number of adults and children who are still alive and on treatment at 12 months after initiating ART</p>	<p>1,989,019</p>
	<p>Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up</p>	<p>2,214,596</p>
	<p>Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	<p>6,670</p>
	<p>Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	<p>16,596</p>



	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,498
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,590
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,978
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125,376
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31,873
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,568
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,943
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54,635



	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	235,885
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36,702
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,473
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,857
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,621
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	5,704



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,670
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	110,574
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29,743
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,631
	Age/Sex: 15-19 Female	13,641



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41,481
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	226,029
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31,808
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator:)	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	95,953
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	696,871



	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98,724
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	999,381
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	101,523
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	729,331
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	107,384
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of	1,075,286



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	46
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	46
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46
	CD4: Number of laboratories that perform this testing	46
	CD4: Number of laboratories that participate in this PT program	46
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46
	Early infant diagnostics: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that participate in this PT program	



	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST):	



	Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	CD4: Number of laboratories that participate in this PT program	0
	CD4: Number of laboratories that perform this testing	0
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	Early infant diagnostics: Number of laboratories that participate in this PT program	0
	Early infant diagnostics: Number of laboratories that perform this testing	0
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful	984



	passing criteria in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,923
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV viral load: Number of laboratories that participate in this PT program	0
	HIV viral load: Number of laboratories that perform this testing	0
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF):	0



	Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	779
	By Graduates: Doctors	
	By Graduates: Nurses	548
	By Graduates: Midwives	231
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	450
	Sum of Graduates disaggregated	1,229



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9464	Africare	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9526	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
9562	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9569	Edication Development Center	NGO	U.S. Agency for International Development	GHP-State	311,442
9610	International Organization for Migration	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	338,000
9816	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
11498	U.S. Peace Corps	Other USG	U.S. Peace Corps	GHP-State	200,000



		Agency			
11500	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,675,542
12510	South Africa Partners	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12887	AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13000	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13558	Human Science Research Council of South Africa	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13567	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
13570	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13577	HIV Managed Care Solutions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13585	Shout It Now	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13608	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13618	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
13619	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13644	University of Cape Town	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13682	Health Information Systems Program	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13688	Health and Development Africa	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13695	Epicentre AIDS Risk Management	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	400,000



			Prevention		
13709	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
13750	University of Stellenbosch, South Africa	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13761	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13767	Re-Action!	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13771	Howard University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



13789	South African Clothing & Textile Workers' Union	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13793	TB/HIV Care	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13797	Health Systems Trust	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13798	Soul City	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13800	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13888	Population	NGO	U.S. Department	GHP-State	0



	Services International		of Health and Human Services/Centers for Disease Control and Prevention		
13903	Community Media Trust	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13904	TB/HIV Care	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13923	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	175,000
13938	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14126	South Africa Partners	NGO	U.S. Department of Health and	GHP-State	0



			Human Services/Centers for Disease Control and Prevention		
14291	Hospice and Palliative Care Assn. Of South Africa	NGO	U.S. Agency for International Development	GHP-State	14,462,086
14295	FHI 360	NGO	U.S. Agency for International Development	GHP-State	10,973,477
14617	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
14623	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	400,000
14631	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	13,127,298
14667	Tulane University	University	U.S. Agency for International Development	GHP-State	0
14846	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	0
16372	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	12,649,187
16583	Aurum Health Research	NGO	U.S. Department of Health and Human	GHP-State	1,107,437



			Services/Centers for Disease Control and Prevention		
16584	Beyond Zero	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,148,602
16772	National Department of Health	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,320,863
16773	South African National AIDS Council	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	675,000
16775	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,340,825
16807	University of Stellenbosch, South Africa	University	U.S. Department of Health and Human Services/Centers	GHP-State	2,320,106



			for Disease Control and Prevention		
16808	University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,214,519
16929	TBD	TBD	Redacted	Redacted	Redacted
16979	Regional Psychosocial Support Initiative, South Africa	NGO	U.S. Agency for International Development	GHP-State	0
16980	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	1,044,938
16981	Africa Health Placements	NGO	U.S. Agency for International Development	GHP-State	0
16982	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	6,772,833
16984	South Africa Partners	NGO	U.S. Agency for International Development	GHP-State	635,060
16987	Childline Mpumalanga	NGO	U.S. Agency for International Development	GHP-State	501,652
16988	Kheth'Impilo	NGO	U.S. Agency for International	GHP-State	0



			Development		
16989	Childwelfare Bloemfontein & Childline Free State	NGO	U.S. Agency for International Development	GHP-State	130,768
16990	Children in Distress	NGO	U.S. Agency for International Development	GHP-State	0
16991	Future Families	Implementing Agency	U.S. Agency for International Development	GHP-State	0
16992	HIVSA	Implementing Agency	U.S. Agency for International Development	GHP-State	0
16993	NACOSA (Networking AIDS Community of South Africa)	Implementing Agency	U.S. Agency for International Development	GHP-State	102,989
17017	National Association of Childcare Workers	NGO	U.S. Agency for International Development	GHP-State	0
17018	AgriAIDS	NGO	U.S. Agency for International Development	GHP-State	2,486,063
17019	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	1,990,755
17020	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	2,269,511
17021	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	15,295,364
17022	The South-to-South	Private Contractor	U.S. Agency for International	GHP-State	3,328,779



	Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)		Development		
17023	Broadreach	NGO	U.S. Agency for International Development	GHP-State	19,952,015
17024	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	317,040
17025	Wits Health Consortium, Health Economics and Epidemiology Research Office	Implementing Agency	U.S. Agency for International Development	GHP-State	3,000,000
17026	Mothers to Mothers (M2M)	Implementing Agency	U.S. Agency for International Development	GHP-State	1,348,824
17027	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	1,439,732
17028	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	0
17029	Witkoppen Health & Welfare Centre (WHWC)	NGO	U.S. Agency for International Development	GHP-State	1,370,777
17033	Medical Research Council	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



17036	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	19,098,335
17037	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	2,466,232
17038	Maternal, Adolscent and Child Health (MatCH)	Implementing Agency	U.S. Agency for International Development	GHP-State	11,510,428
17039	Broadreach	NGO	U.S. Agency for International Development	GHP-State	3,890,131
17043	Wits Reproductive Health& HIV Institute	NGO	U.S. Agency for International Development	GHP-State	0
17046	Kheth'Impilo	NGO	U.S. Agency for International Development	GHP-State	6,407,281
17452	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	750,000
17459	Human Sciences Research Council	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17493	National Health Laboratory	Parastatal	U.S. Department of Health and	GHP-State	320,608



	Services		Human Services/Centers for Disease Control and Prevention		
17505	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17506	Beyond Zero	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	371,003
17507	Kheth'Impilo	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	989,614
17510	Macro Atlanta	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17512	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human	GHP-State	584,860



			Services/Centers for Disease Control and Prevention		
17533	South Africa Partners	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,004,426
17536	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
17537	Johns Hopkins Health and Education in South Africa	NGO	U.S. Agency for International Development	GHP-State	5,448,669
17538	Johns Hopkins Health and Education in South Africa	NGO	U.S. Agency for International Development	GHP-State	0
17767	Broadreach	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17768	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	57,784



17769	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,625,000
17790	The Centre for HIV and AIDS Prevention Studies	NGO	U.S. Agency for International Development	GHP-State	170,360
17791	Grassroots Soccer	NGO	U.S. Agency for International Development	GHP-State	0
17801	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	281,939
17968	Wits Health Consortium, Reproductive Health Research Unit	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	511,555
17969	University of Stellenbosch, South Africa	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
17980	South African Military Health Service	Host Country Government Agency	U.S. Department of Defense	GHP-State	0



17981	Society for Family Health - South Africa	NGO	U.S. Department of Defense	GHP-State	0
18021	Health Information Systems Program	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,493,862
18022	TBD	TBD	Redacted	Redacted	Redacted
18023	TBD	TBD	Redacted	Redacted	Redacted
18083	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
18231	TBD	TBD	Redacted	Redacted	Redacted
18254	TBD	TBD	Redacted	Redacted	Redacted
18298	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,000,000
18299	TBD	TBD	Redacted	Redacted	Redacted
18300	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	350,000
18307	UCSF CDC HQ	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000



18313	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
18314	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
18321	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	3,607,311
18480	Foundation for Professional Development	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	40,163,484
18481	Health Systems Trust	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,917,835
18482	TB/HIV Care	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	6,513,431



			Control and Prevention		
18483	Wits Health Consortium (Pty) Limited	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,392,908
18484	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,070,929



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9464	Mechanism Name: Africare
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Africare	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9464			
Mechanism Name: Africare			
Prime Partner Name: Africare			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9526	Mechanism Name: Supply Chain Management System (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9526			
Mechanism Name: Supply Chain Management System (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 9562	Mechanism Name: National Alliance of State and Territorial AIDS Directors
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9562		
Mechanism Name:	National Alliance of State and Territorial AIDS Directors		
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 9569	Mechanism Name: South Africa School-Based Sexuality and HIV Prevention Education Activity
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Edication Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 311,442	
Applied Pipeline Amount: 1,672,131	
Total All Funding Sources and Applied Pipeline Amount: 1,983,573	
Funding Source	Funding Amount
GHP-State	311,442

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	11,442
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Education	100,000

Budget Code Information

Mechanism ID:	9569		
Mechanism Name:	South Africa School-Based Sexuality and HIV Prevention Education		
Prime Partner Name:	Activity Edication Development Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	311,442	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
------------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	101,820
PP_PREV_DSD	Total number of people in the target population	488,312
PP_PREV_DSD	Aggregated Age/sex: <15 Male	9,560
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	9,560
PP_PREV_DSD	Aggregated Age/sex: <15 Female	33,391
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	45,397

Implementing Mechanism Details

Mechanism ID: 9610	Mechanism Name: Migrants and Mobile Populations HIV Prevention Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: International Organization for Migration	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 338,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 338,000	
Funding Source	Funding Amount
GHP-State	338,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000
-------------------------	--------



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research



Budget Code Information

Mechanism ID:	9610		
Mechanism Name:	Migrants and Mobile Populations HIV Prevention Program		
Prime Partner Name:	International Organization for Migration		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	338,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	33,800
PP_PREV_DSD	Total number of people in the target population	137,108
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,600
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	17,700
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,200
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	12,300

Implementing Mechanism Details



Mechanism ID: 9816	Mechanism Name: The Thogomleo Project (AIDSTAR)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9816			
Mechanism Name: The Thogomleo Project (AIDSTAR)			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 11498	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 225,000	
Total All Funding Sources and Applied Pipeline Amount: 425,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

Education	60,000
Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 11498			
Mechanism Name: U.S. Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	120,000	0
Prevention	HVAB	0	0
Prevention	HVOP	80,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	110
PP_PREV_DSD	Total number of people in the target population	9,500
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	55
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	55
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,880
PP_PREV_TA	Total number of people in the target population	371,500
PP_PREV_TA	Aggregated Age/sex: <15 Male	500
PP_PREV_TA	Aggregated Age/sex: 15+ Male	2,438
PP_PREV_TA	Aggregated Age/sex: <15 Female	500
PP_PREV_TA	Aggregated Age/sex: 15+ Female	2,442
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,432
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,433
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,865

Implementing Mechanism Details



Mechanism ID: 11500	Mechanism Name: Community Grants
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,675,542	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,675,542	
Funding Source	Funding Amount
GHP-State	1,675,542

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	11500		
Mechanism Name:	Community Grants		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	223,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,079,542	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	149,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	223,500	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12510	Mechanism Name: South Africa Partners
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12510		
Mechanism Name:	South Africa Partners		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12887	Mechanism Name: Comp Prev GH000233
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12887



Mechanism Name:	Comp Prev GH000233		
Prime Partner Name:	AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13000	Mechanism Name: Council of Scientific and Industrial Research
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13000		
Mechanism Name:	Council of Scientific and Industrial Research		
Prime Partner Name:	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13558	Mechanism Name: GH00258
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Human Science Research Council of South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13558			
Mechanism Name: GH000258			
Prime Partner Name: Human Science Research Council of South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13567	Mechanism Name: GH000251
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13567			
Mechanism Name: GH000251			
Prime Partner Name: University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13570	Mechanism Name: MMC GH000248
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13570			
Mechanism Name: MMC GH000248			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13577	Mechanism Name: GH000291
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: HIV Managed Care Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13577			
Mechanism Name: GH000291			
Prime Partner Name: HIV Managed Care Solutions			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13585	Mechanism Name: GH000285
----------------------------	---------------------------------

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Shout It Now	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13585			
Mechanism Name: GH000285			
Prime Partner Name: Shout It Now			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13608	Mechanism Name: GH000324
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13608		
Mechanism Name:	GH000324		
Prime Partner Name:	University of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 13618	Mechanism Name: GH000249
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13618		
Mechanism Name:	GH000249		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13619	Mechanism Name: GH000237
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13619		
Mechanism Name:	GH000237		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13644	Mechanism Name: GH000371
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Cape Town	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13644			
Mechanism Name: GH000371			
Prime Partner Name: University of Cape Town			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13682	Mechanism Name: GH00460
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Information Systems Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13682			
Mechanism Name: GH00460			
Prime Partner Name: Health Information Systems Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13688	Mechanism Name: GH00252
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health and Development Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13688			
Mechanism Name: GH000252			
Prime Partner Name: Health and Development Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13695		Mechanism Name: GH00372	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Epicentre AIDS Risk Management			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)



Condom programming	1,250
Motor Vehicles: Leased	128,764
Gender: Gender Equality	1,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: GBV	1,250
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Human Resources for Health	2,500
Water	75,000



Budget Code Information

Mechanism ID: 13695			
Mechanism Name: GH00372			
Prime Partner Name: Epicentre AIDS Risk Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13709	Mechanism Name: University of Washington - ITECH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13709			
Mechanism Name: University of Washington - ITECH			
Prime Partner Name: University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13750	Mechanism Name: GH000320
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Stellenbosch, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 99,510	
Total All Funding Sources and Applied Pipeline Amount: 99,510	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13750			
Mechanism Name: GH000320			
Prime Partner Name: University of Stellenbosch, South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	168



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By: Known positives at entry	136
PMTCT_STAT_DSD	By: Number of new positives identified	32
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	168
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	699
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,656

Implementing Mechanism Details

Mechanism ID: 13761	Mechanism Name: District HRH GH000162
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Aurum Health Research	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 13761			
Mechanism Name: District HRH GH000162			
Prime Partner Name: Aurum Health Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13767	Mechanism Name: GH000255
----------------------------	---------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Re-Action!	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13767			
Mechanism Name: GH000255			
Prime Partner Name: Re-Action!			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13771	Mechanism Name: GH000391
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Howard University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13771			
Mechanism Name: GH000391			
Prime Partner Name: Howard University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 13789	Mechanism Name: GH000265
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South African Clothing & Textile Workers' Union	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13789		
Mechanism Name:	GH000265		
Prime Partner Name:	South African Clothing & Textile Workers' Union		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13793	Mechanism Name: Comprehensive HIV
----------------------------	--



	prevention GH000306
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TB/HIV Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13793		
Mechanism Name:	Comprehensive HIV prevention GH000306		
Prime Partner Name:	TB/HIV Care		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	666
PrEP_NEW_DSD	Female 20-24	666

Implementing Mechanism Details

Mechanism ID: 13797		Mechanism Name: District Support GH000175	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Health Systems Trust			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13797			
Mechanism Name: District Support GH000175			
Prime Partner Name: Health Systems Trust			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13798	Mechanism Name: GH000294
----------------------------	---------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Soul City	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13798			
Mechanism Name: GH000294			
Prime Partner Name: Soul City			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13800	Mechanism Name: TB Capacity Building GH000388
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13800		
Mechanism Name:	TB Capacity Building GH000388		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13888	Mechanism Name: Combination Prevention GH000243
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13888		
Mechanism Name:	Combination Prevention GH000243		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13903	Mechanism Name: GH000293
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Community Media Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13903



Mechanism Name: GH000293			
Prime Partner Name: Community Media Trust			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13904	Mechanism Name: Key Pops GH000257
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TB/HIV Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13904			
Mechanism Name: Key Pops GH000257			
Prime Partner Name: TB/HIV Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13923	Mechanism Name: NEPI
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 175,000	
Applied Pipeline Amount: 225,000	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	175,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	170,000
----------------------------	---------

Budget Code Information



Mechanism ID:	13923		
Mechanism Name:	NEPI		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	175,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	779
HRH_PRE	By Graduates: Nurses	548
HRH_PRE	By Graduates: Midwives	231
HRH_PRE	Sum of Graduates disaggregated	779

Implementing Mechanism Details

Mechanism ID: 13938	Mechanism Name: Catholic Medical Mission Board
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13938		
Mechanism Name:	Catholic Medical Mission Board		
Prime Partner Name:	Catholic Medical Mission Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14126	Mechanism Name: MARPs GH000250
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14126			
Mechanism Name: MARPs GH000250			
Prime Partner Name: South Africa Partners			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14291	Mechanism Name: Care and Support to Improve Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Hospice and Palliative Care Assn. Of South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 14,462,086	
Applied Pipeline Amount: 754,909	



Total All Funding Sources and Applied Pipeline Amount: 15,216,995	
Funding Source	Funding Amount
GHP-State	14,462,086

Cross-Cutting Budget Attribution(s)

Human Resources for Health	135,501
Gender: Gender Equality	67,750
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	135,501

Budget Code Information

Mechanism ID: 14291			
Mechanism Name: Care and Support to Improve Patient Outcomes			
Prime Partner Name: Hospice and Palliative Care Assn. Of South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	9,307,393	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	385,628	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	2,361,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	6,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	2,371,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	29,785	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14295	Mechanism Name: Capacity Development and Support Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 10,973,477	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,973,477	
Funding Source	Funding Amount
GHP-State	10,973,477

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	308,186
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support



Gender: GBV	308,186
Focus Area:	GBV Prevention
Motor Vehicles: Purchased	102,611
Water	500,000

Budget Code Information

Mechanism ID:	14295		
Mechanism Name:	Capacity Development and Support Program		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	7,524,748	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,024,240	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	424,489	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	389,506
PP_PREV_DSD	Total number of people in the target population	2,026,283
PP_PREV_DSD	Aggregated Age/sex: <15 Male	38,951
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	155,801
PP_PREV_DSD	Aggregated Age/sex: <15 Female	38,951
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	155,801
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	292,837
HTC_TST_DSD	Age/sex: 10-14 Male	5,649
HTC_TST_DSD	Age/sex: 15-19 Male	23,076
HTC_TST_DSD	Age/sex: 20-24 Male	45,915
HTC_TST_DSD	Age/sex: 25-49 Male	17,186
HTC_TST_DSD	Age/sex: 50+ Male	17,186



HTC_TST_DSD	Age/sex: 10-14 Female	24,176
HTC_TST_DSD	Age/sex: 15-19 Female	32,862
HTC_TST_DSD	Age/sex: 20-24 Female	48,822
HTC_TST_DSD	Age/sex: 25-49 Female	16,195
HTC_TST_DSD	Age/sex: 50+ Female	16,195
HTC_TST_DSD	Sum of Age/Sex disaggregates	247,262
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	628
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	2,568
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	5,108
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,913
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1,913
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	2,761
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	3,754
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	5,576
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,850
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,850
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	14,642
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	117,134
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,642
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	146,419
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	29,284
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	263,553
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	292,837
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,317
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	13,126
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,317



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	17,332
HTC_TST_DSD	Test Result by Age: Positive: <1	783
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2,633
HTC_TST_DSD	Age/sex: <1	6,934
HTC_TST_DSD	Age/sex: 1-9	23,129
HTC_TST_DSD	Service Delivery Point (Community): Index testing	29,284
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	131,777
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	117,134
HTC_TST_DSD	Service Delivery Point (Community): Other	14,642
GEND_GBV_DSD	Number of people receiving post-GBV care	1,976
GEND_GBV_DSD	Age/Sex: 10-14 Female	668
GEND_GBV_DSD	Age/Sex: 20-24 Female	649
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	668
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	989
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	989
GEND_GBV_DSD	Age/Sex: 15-19 Female	649
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,502
OVC_SERV_DSD	Age/Sex: 18+ Male	620
OVC_SERV_DSD	Age/Sex: 18+ Female	775
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,395
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	9,530
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	11,626
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	23,250
OVC_SERV_TA	Age/Sex: 18+ Male	930
OVC_SERV_TA	Age/Sex: 18+ Female	1,164
OVC_SERV_TA	Sum of Age/Sex disaggregates	2,094



Implementing Mechanism Details

Mechanism ID: 14617	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14617		
Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14623	Mechanism Name: Increasing Services to Survivors of Sexual Assault
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Professional Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	287,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	113,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation

Budget Code Information

Mechanism ID: 14623			
Mechanism Name: Increasing Services to Survivors of Sexual Assault			
Prime Partner Name: Foundation for Professional Development			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	400,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
GEND_GBV_DSD	Number of people receiving post-GBV care	17,290
GEND_GBV_DSD	Age/Sex: 20-24 Female	8,645
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	17,290
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	10,348
GEND_GBV_DSD	Age/Sex: 15-19 Female	8,645

Implementing Mechanism Details

Mechanism ID: 14631	Mechanism Name: Government Capacity Building and Support Mechanism
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 13,127,298	
Applied Pipeline Amount: 318,302	
Total All Funding Sources and Applied Pipeline Amount: 13,445,600	
Funding Source	Funding Amount
GHP-State	13,127,298

Cross-Cutting Budget Attribution(s)

Gender: GBV	861,006
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	861,006
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	1,000,000
Water	300,000

Budget Code Information

Mechanism ID:	14631		
Mechanism Name:	Government Capacity Building and Support Mechanism		
Prime Partner Name:	Pact, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	13,127,298	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	77,000
OVC_SERV_DSD	Age/Sex: 18+ Male	6,209
OVC_SERV_DSD	Age/Sex: 18+ Female	13,811
OVC_SERV_DSD	Sum of Age/Sex disaggregates	20,020
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	26,952
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	30,028
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	200,000



OVC_SERV_TA	Age/Sex: 18+ Male	16,000
OVC_SERV_TA	Age/Sex: 18+ Female	35,998
OVC_SERV_TA	Sum of Age/Sex disaggregates	51,998

Implementing Mechanism Details

Mechanism ID: 14667	Mechanism Name: Tulane University - Compiling Evidence Base for Orphans and Vulnerable Children		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Tulane University			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 0	
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14667		
Mechanism Name:	Tulane University - Compiling Evidence Base for Orphans and Vulnerable Children		
Prime Partner Name:	Tulane University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	0	0
------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14846	Mechanism Name: Strategic Information for Evidence-Based Management of HIV and Related Health Program in South Africa
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 2,548,509	
Total All Funding Sources and Applied Pipeline Amount: 2,548,509	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14846
Mechanism Name:	Strategic Information for Evidence-Based Management of HIV and Related Health Program in South Africa
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16372	Mechanism Name: Voluntary Medical Male Circumcision Service Delivery II Project (VMMC II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 12,649,187	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 12,649,187	
Funding Source	Funding Amount
GHP-State	12,649,187

Cross-Cutting Budget Attribution(s)

Condom programming	1,500,000
Water	1,000

Budget Code Information



Mechanism ID:	16372		
Mechanism Name:	Voluntary Medical Male Circumcision Service Delivery II Project (VMMC II)		
Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	12,649,187	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	191,440
VMMC_CIRC_DSD	By Age: 10-14	22,971
VMMC_CIRC_DSD	By Age: 15-19	57,436
VMMC_CIRC_DSD	By Age: 20-24	47,869
VMMC_CIRC_DSD	By Age: 25-29	47,865
VMMC_CIRC_DSD	By Age: 30-49	9,558
VMMC_CIRC_DSD	By Age: 50+	5,741
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	134,017
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	191,440
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	191,440

Implementing Mechanism Details

Mechanism ID: 16583	Mechanism Name: District Support GH00887
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Aurum Health Research	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,107,437	
---	--



Applied Pipeline Amount: 8,684,551	
Total All Funding Sources and Applied Pipeline Amount: 9,791,988	
Funding Source	Funding Amount
GHP-State	1,107,437

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16583			
Mechanism Name: District Support GH000887			
Prime Partner Name: Aurum Health Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,107,437	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	96,234
PMTCT_ART_TA	New on ART	15,175
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	6,504
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	96,234
PMTCT_STAT_TA	Number of new ANC and L&D clients	98,195
PMTCT_STAT_TA	By: Known positives at entry	11,033
PMTCT_STAT_TA	By: Number of new positives identified	16,633



PMTCT_STAT_TA	Sum of Positives Status disaggregates	27,666
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	78
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	465
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	1,817
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	111
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	677
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	3,120
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	5,485
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	64
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	7,859
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	5
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): <15	615
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 15-19	3,716
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 20-24	14,715
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 25-49	42,458
PMTCT_STAT_TA	By Age (DREAMS SNUs ONLY): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,573
PP_PREV_DSD	Total number of people in the target population	0
PP_PREV_DSD	Aggregated Age/sex: <15 Male	293
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,818
PP_PREV_DSD	Aggregated Age/sex: <15 Female	293



PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,171
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	427,473
HTC_TST_TA	Age/sex: 10-14 Male	0
HTC_TST_TA	Age/sex: 15-19 Male	0
HTC_TST_TA	Age/sex: 20-24 Male	2,644
HTC_TST_TA	Age/sex: 25-49 Male	44,352
HTC_TST_TA	Age/sex: 50+ Male	8,456



HTC_TST_TA	Age/sex: 10-14 Female	0
HTC_TST_TA	Age/sex: 15-19 Female	3,395
HTC_TST_TA	Age/sex: 20-24 Female	15,332
HTC_TST_TA	Age/sex: 25-49 Female	81,404
HTC_TST_TA	Age/sex: 50+ Female	8,459
HTC_TST_TA	Sum of Age/Sex disaggregates	164,042
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	474
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	7,796
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	1,438
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	579
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	2,595
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	13,566
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	1,439
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,830
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	158,145
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,830
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	243,660
HTC_TST_TA	Sum of Aggregated Age/Sex <15	25,660
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	401,805
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	427,465
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	1,666
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	20,559
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	1,671



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	31,668
HTC_TST_TA	Test Result by Age: Positive: <1	287
HTC_TST_TA	Test Result by Age: Positive: 1-9	285
HTC_TST_TA	Age/sex: <1	1,694
HTC_TST_TA	Age/sex: 1-9	1,694
HTC_TST_TA	Service Delivery Point (Facility): VCT	360,827
HTC_TST_TA	Service Delivery Point (Facility): VMMC	426
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	62,312
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	19,391
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	20,337
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	579
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	7,266



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	579
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10,983
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,666
OVC_SERV_DSD	Age/Sex: 18+ Male	632
OVC_SERV_DSD	Age/Sex: 18+ Female	2,407
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,039
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,639
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,263
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,396
OVC_SERV_TA	Age/Sex: 18+ Male	520
OVC_SERV_TA	Age/Sex: 18+ Female	1,975
OVC_SERV_TA	Sum of Age/Sex disaggregates	2,495
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,557
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	11,607
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	320
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	3,919

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	320
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,045
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	561,572
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	16,841
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	207,787
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	16,841
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	320,114
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	2,060
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	21,671
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	33
PMTCT_EID_TA	Sum of Infant Age disaggregates	21,704
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	317
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_TA	Number of adults and children receiving antiretroviral	542,101



	therapy (ART)	
TX_CURR_TA	Age/Sex: 15-19 Male	0
TX_CURR_TA	Age/Sex: 15-19 Female	6,537
TX_CURR_TA	Sum of Age/Sex disaggregations	6,537
TX_CURR_TA	Aggregated Age/Sex: <15 Male	16,229
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	210,372
TX_CURR_TA	Aggregated Age/Sex: <15 Female	16,224
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	306,100
TX_CURR_TA	Sum of Aggregated Age/Sex <15	32,453
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	516,472
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	548,925
TX_CURR_TA	Age/Sex: <1	3,067
TX_CURR_TA	Age/Sex: 1-9	3,464
TX_CURR_TA	Age/Sex: 10-14 Male	0
TX_CURR_TA	Age/Sex: 10-14 Female	0
TX_CURR_TA	Age/Sex: 20-24 Male	5,983
TX_CURR_TA	Age/Sex: 25-49 Male	87,366
TX_CURR_TA	Age/Sex: 50+ Male	16,337
TX_CURR_TA	Age/Sex: 20-24 Female	29,532
TX_CURR_TA	Age/Sex: 25-49 Female	154,799
TX_CURR_TA	Age/Sex: 50+ Female	16,233
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	107,593
TX_NEW_TA	By Age/Sex: 1-9	596
TX_NEW_TA	By Age/Sex: 10-14 Male	0
TX_NEW_TA	By Age/Sex: 15-19 Male	0
TX_NEW_TA	By Age/Sex: 20-24 Male	896
TX_NEW_TA	By Age/Sex: 25-49 Male	14,210
TX_NEW_TA	By Age/Sex: 50+ Male	2,586
TX_NEW_TA	By Age/Sex: 10-14 Female	0
TX_NEW_TA	By Age/Sex: 15-19 Female	1,031
TX_NEW_TA	By Age/Sex: 20-24 Female	4,659



TX_NEW_TA	By Age/Sex: 25-49 Female	25,371
TX_NEW_TA	By Age/Sex: 50+ Female	2,589
TX_NEW_TA	Sum of Age/Sex disaggregates	51,342
TX_NEW_TA	Aggregated Grouping by Age: <1	466
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	3,229
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	39,810
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	3,229
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	61,340
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	107,608
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	0
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	441,039
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	490,045
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	13,020
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	167,434



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	13,020
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	246,312
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	14,462
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	187,361
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	14,462
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	273,765
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	280,168
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	298,053
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,838
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,820
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,118
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49,177
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and	9,048



	children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,656
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,464
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87,798
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,148
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,946
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,946
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	0



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,965
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51,886
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,112
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,904
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,504
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	93,676



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,695
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,455
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104,125
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,452
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	159,113
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,963
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109,917
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,963
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	170,223



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 16584	Mechanism Name: District Support GH000889
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Beyond Zero	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,148,602	
Applied Pipeline Amount: 4,272,739	
Total All Funding Sources and Applied Pipeline Amount: 6,421,341	
Funding Source	Funding Amount
GHP-State	2,148,602

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Human Resources for Health	1,208,771



Budget Code Information

Mechanism ID: 16584			
Mechanism Name: District Support GH000889			
Prime Partner Name: Beyond Zero			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	489,041	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	377,485	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	830,282	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	225,896	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	225,898	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,423
PMTCT_ART_TA	New on ART	2,416
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	5,369
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	38,423
PMTCT_STAT_TA	Number of new ANC and L&D clients	39,205
PMTCT_STAT_TA	By: Known positives at entry	11,176
PMTCT_STAT_TA	By: Number of new positives identified	5,770
PMTCT_STAT_TA	Sum of Positives Status disaggregates	16,946
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	275,233
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,757
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	99,064
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,757
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	148,647
HTC_TST_TA	Sum of Aggregated Age/Sex <15	27,514
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	247,711
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	275,225



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	4,095
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	31,049
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	4,095
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	45,235
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	27,536
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	13,776
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	13,776
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	13,776
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	27,536
HTC_TST_TA	Service Delivery Point (Facility): VCT	41,325
HTC_TST_TA	Service Delivery Point (Facility): VMMC	14,006
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	41,324
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	41,074
HTC_TST_TA	Service Delivery Point (Facility): Index testing	41,316
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,951
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	12,532



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	607
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,299
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	606
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,454
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,543
OVC_SERV_DSD	Age/Sex: 18+ Male	380
OVC_SERV_DSD	Age/Sex: 18+ Female	381
OVC_SERV_DSD	Sum of Age/Sex disaggregates	761
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	891
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,861
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,318
OVC_SERV_TA	Age/Sex: 18+ Male	797
OVC_SERV_TA	Age/Sex: 18+ Female	799
OVC_SERV_TA	Sum of Age/Sex disaggregates	1,596
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0



TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,462
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,136
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	315
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,291
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	391
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,459
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	5
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	145
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	8
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	212,713
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	10,635
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	76,573
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	10,636
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	115,872



TB_SCREENDX_TA	Screen Results: Screened Positive for TB	102,105
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	101,813
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	10,219
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	88,799
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	5,110
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	3,833
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	3,835
PMTCT_EID_TA	Sum of Infant Age disaggregates	7,668
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	56
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	56
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	202,540
TX_CURR_TA	Aggregated Age/Sex: <15 Male	10,121
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	72,866
TX_CURR_TA	Aggregated Age/Sex: <15 Female	10,123
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	109,292
TX_CURR_TA	Sum of Aggregated Age/Sex <15	20,244
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	182,158
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	202,402



TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	54,643
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2,734
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	19,670
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	2,734
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	29,509
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	54,647
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	164,034
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	182,673
TX_PVLS_TA	Numerator: Indication: Routine	131,223
TX_PVLS_TA	Numerator: Indication: Targeted	32,810
TX_PVLS_TA	Denominator: Indication: Routine	146,217
TX_PVLS_TA	Denominator: Indication: Targeted	36,480
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	8,204
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	59,055
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	8,204
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	88,573
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	9,134
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	65,777
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	9,134
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	98,688
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	113,966
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	121,305
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,707
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41,071
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,707
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	61,629
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,057
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42,918
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total	6,057



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66,236

Implementing Mechanism Details

Mechanism ID: 16772	Mechanism Name: NDOH (CDC GH001172)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,320,863	
Applied Pipeline Amount: 2,272,047	
Total All Funding Sources and Applied Pipeline Amount: 3,592,910	
Funding Source	Funding Amount
GHP-State	1,320,863

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16772
Mechanism Name:	NDOH (CDC GH001172)
Prime Partner Name:	National Department of Health



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	420,794	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	109,682	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	100,387	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16773	Mechanism Name: South African National AIDS Council (CDC GH001173)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South African National AIDS Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 675,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 675,000	
Funding Source	Funding Amount
GHP-State	675,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16773			
Mechanism Name: South African National AIDS Council (CDC GH001173)			
Prime Partner Name: South African National AIDS Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	27,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	137,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	110,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16775	Mechanism Name: AURUM Correctional Services (CDC GH001175)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Aurum Health Research	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,340,825	
Applied Pipeline Amount: 3,086,296	
Total All Funding Sources and Applied Pipeline Amount: 6,427,121	
Funding Source	Funding Amount
GHP-State	3,340,825

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,129,878
Motor Vehicles: Purchased	248,604
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	564,939
Focus Area:	Training of health workers and community outreach workers

Budget Code Information

Mechanism ID: 16775			
Mechanism Name: AURUM Correctional Services (CDC GH001175)			
Prime Partner Name: Aurum Health Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	457,951	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	951,896	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,430,978	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_ART_TA	New on ART	0
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	0



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_TA	Number of new ANC and L&D clients	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	14,766
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	738
VMMC_CIRC_DSD	By Age: 15-19	3,986
VMMC_CIRC_DSD	By Age: 20-24	3,695
VMMC_CIRC_DSD	By Age: 25-29	5,906
VMMC_CIRC_DSD	By Age: 30-49	296
VMMC_CIRC_DSD	By Age: 50+	146
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,565
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	14,767
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	10,958
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	3,805
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	70,099
KP_PREV_DSD	Total estimated number of key population in the catchment area	128,677
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	70,099



KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	128,677
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,912
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	68,816
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,096
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	70,912
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	70,912
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	8,255
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	252
HTC_TST_DSD	Service Delivery Point (Facility): VCT	62,426
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	254,653
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	245,844
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,808
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	254,652
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	254,652
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	29,444



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,059
HTC_TST_TA	Service Delivery Point (Facility): VCT	217,994
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,033
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,182
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,470
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,185
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,543
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	5,641
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,320
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	146
TB_ART_DSD	The number of registered new and relapse TB cases	633



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	855
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	615
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,065
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,236
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,000
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	67



TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	20,173
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	19,895
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	278
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	100,035
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	97,278
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	2,756
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	8,181
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,725
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,567
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	158
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,725
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,725
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	20,955
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	20,332
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	623
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	20,955
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	20,955
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,206
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,187
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	19
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,206



TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,795
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	4,650
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	157
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	4,807
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,547
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,057
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,419
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	128
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4,914
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	143
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	16,738
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,597
TX_PVLS_TA	Numerator: Indication: Targeted	558
TX_PVLS_TA	Denominator: Indication: Targeted	620
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	16,214
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	505
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	0
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	18,027



TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	560
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,713
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,987
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,585
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,873
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	135
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,106
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,904
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment	12,161



	at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	339
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,542
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	363

Implementing Mechanism Details

Mechanism ID: 16807	Mechanism Name: University of Stellenbosch Capacity Building (CDC GH001536)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Stellenbosch, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 2,320,106	
Applied Pipeline Amount: 468,998	
Total All Funding Sources and Applied Pipeline Amount: 2,789,104	
Funding Source	Funding Amount
GHP-State	2,320,106

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,200,000
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	10,000
Key Populations: FSW	14,000
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	14,000
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	16807		
Mechanism Name:	University of Stellenbosch Capacity Building (CDC GH001536)		
Prime Partner Name:	University of Stellenbosch, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	372,821	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	428,823	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	34,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	357,820	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	106,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	720,642	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	25,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16808	Mechanism Name: UKZA CAPRISA Advanced Clinical Care Centres (CDC GH001142)
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,214,519	
Applied Pipeline Amount: 1,785,481	
Total All Funding Sources and Applied Pipeline Amount: 3,000,000	
Funding Source	Funding Amount
GHP-State	1,214,519

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	44,583
---------------------------	--------

Budget Code Information

Mechanism ID:	16808		
Mechanism Name:	UKZA CAPRISA Advanced Clinical Care Centres (CDC GH001142)		
Prime Partner Name:	University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	80,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	354,519	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16929	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16979	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Regional Psychosocial Support Initiative (REPSSI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Regional Psychosocial Support Initiative, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16979		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Regional Psychosocial Support Initiative		
Prime Partner Name:	(REPSSI) Regional Psychosocial Support Initiative, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16980	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,044,938	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,044,938	
Funding Source	Funding Amount
GHP-State	1,044,938



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16980			
Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	762,999	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	90,582	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	191,357	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16981	Mechanism Name: Africa Health Placements NPC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Africa Health Placements	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16981		
Mechanism Name:	Africa Health Placements NPC		
Prime Partner Name:	Africa Health Placements		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	55

Implementing Mechanism Details

Mechanism ID: 16982	Mechanism Name: A Comprehensive Community-Based HIV Prevention, Counselling and Testing Programme for Reduced HIV Incidence
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Foundation for Professional Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,772,833	
Applied Pipeline Amount: 562,721	
Total All Funding Sources and Applied Pipeline Amount: 7,335,554	
Funding Source	Funding Amount
GHP-State	6,772,833

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	150,500
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	16982
Mechanism Name:	A Comprehensive Community-Based HIV Prevention, Counselling and
Prime Partner Name:	Testing Programme for Reduced HIV Incidence



Foundation for Professional Development			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	6,772,833	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	501,196
HTC_TST_DSD	Age/sex: 10-14 Male	1,045
HTC_TST_DSD	Age/sex: 15-19 Male	2,134
HTC_TST_DSD	Age/sex: 20-24 Male	19,809
HTC_TST_DSD	Age/sex: 25-49 Male	58,293
HTC_TST_DSD	Age/sex: 50+ Male	2,086
HTC_TST_DSD	Age/sex: 10-14 Female	1,916
HTC_TST_DSD	Age/sex: 15-19 Female	8,038
HTC_TST_DSD	Age/sex: 20-24 Female	16,364
HTC_TST_DSD	Age/sex: 25-49 Female	18,592
HTC_TST_DSD	Age/sex: 50+ Female	2,836
HTC_TST_DSD	Sum of Age/Sex disaggregates	131,113
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	42
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	235
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	2,178
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	6,412
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	229
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	77
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,044
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,127
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,418



HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	368
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18,264
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	146,142
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	18,271
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	182,680
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	36,535
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	328,822
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	365,357
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	730
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	16,076
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	730
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	23,748
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	190
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	4,726
HTC_TST_DSD	Service Delivery Point (Community): Index testing	50,120
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	225,539
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	200,478
HTC_TST_DSD	Service Delivery Point (Community): Other	25,059

Implementing Mechanism Details

Mechanism ID: 16984	Mechanism Name: South Africa Executive Leadership Program for Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 635,060	
Applied Pipeline Amount: 164,940	
Total All Funding Sources and Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	635,060

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Budget Code Information

Mechanism ID:	16984		
Mechanism Name:	South Africa Executive Leadership Program for Health		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	635,060	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16987	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable
----------------------------	--



	Children (OVC) - Childline Mpumalanga & Limpopo
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Childline Mpumalanga	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 501,652	
Applied Pipeline Amount: 562,677	
Total All Funding Sources and Applied Pipeline Amount: 1,064,329	
Funding Source	Funding Amount
GHP-State	501,652

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Leased	127,438
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	74,491
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID: 16987



Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and		
Prime Partner Name:	Vulnerable Children (OVC) - Childline Mpumalanga & Limpopo		
	Childline Mpumalanga		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	501,652	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	17,000
OVC_SERV_DSD	Age/Sex: 18+ Male	105
OVC_SERV_DSD	Age/Sex: 18+ Female	665
OVC_SERV_DSD	Sum of Age/Sex disaggregates	770
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,007
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	12,223

Implementing Mechanism Details

Mechanism ID: 16988	Mechanism Name: Kheth"Impilo Pharmacist Assistant PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16988		
Mechanism Name:	Kheth"Impilo Pharmacist Assistant PPP		
Prime Partner Name:	Kheth'Impilo		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,037
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,037
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,037
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	113

Implementing Mechanism Details

Mechanism ID: 16989	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childwelfare/Childline Bloemfontein
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Childwelfare Bloemfontein & Childline Free State	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 130,768	
Applied Pipeline Amount: 181,362	
Total All Funding Sources and Applied Pipeline Amount: 312,130	
Funding Source	Funding Amount
GHP-State	130,768

Cross-Cutting Budget Attribution(s)

Gender: GBV	6,458
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	6,458
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID:	16989		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childwelfare/Childline Bloemfontein		
Prime Partner Name:	Childwelfare Bloemfontein & Childline Free State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	130,768	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,500
OVC_SERV_DSD	Age/Sex: 18+ Male	150
OVC_SERV_DSD	Age/Sex: 18+ Female	350
OVC_SERV_DSD	Sum of Age/Sex disaggregates	500
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,450
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,550

Implementing Mechanism Details

Mechanism ID: 16990	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children in Distress	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 960,400	
Total All Funding Sources and Applied Pipeline Amount: 960,400	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	16990		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)		
Prime Partner Name:	Children in Distress		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,392
PP_PREV_DSD	Total number of people in the target population	446,546
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,694
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	5,698
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,646
HTC_TST_DSD	Age/sex: 10-14 Male	330
HTC_TST_DSD	Age/sex: 15-19 Male	680
HTC_TST_DSD	Age/sex: 20-24 Male	190
HTC_TST_DSD	Age/sex: 25-49 Male	91
HTC_TST_DSD	Age/sex: 50+ Male	54
HTC_TST_DSD	Age/sex: 10-14 Female	816
HTC_TST_DSD	Age/sex: 15-19 Female	3,638
HTC_TST_DSD	Age/sex: 20-24 Female	240
HTC_TST_DSD	Age/sex: 25-49 Female	134
HTC_TST_DSD	Age/sex: 50+ Female	65



HTC_TST_DSD	Sum of Age/Sex disaggregates	6,238
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	15
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	82
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	26
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	50
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	438
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	17
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	6
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	470
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,015
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,084
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,077
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,554
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,092
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,646
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	20
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	126
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	61
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	493
HTC_TST_DSD	Test Result by Age: Positive: <1	4
HTC_TST_DSD	Test Result by Age: Positive: 1-9	12
HTC_TST_DSD	Age/sex: <1	98



HTC_TST_DSD	Age/sex: 1-9	310
HTC_TST_DSD	Service Delivery Point (Community): Index testing	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	1,470
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	5,055
HTC_TST_DSD	Service Delivery Point (Community): Other	121
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	26,358
OVC_SERV_DSD	Age/Sex: 18+ Male	2,029
OVC_SERV_DSD	Age/Sex: 18+ Female	2,874
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,903
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	187
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	204
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,629
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,862
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,218
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	383
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	481
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	125
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	7,724
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	13,731

Implementing Mechanism Details



Mechanism ID: 16991	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Future Families
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Future Families	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 300,000	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16991		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Future Families		
Prime Partner Name:	Future Families		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,000
OVC_SERV_DSD	Age/Sex: 18+ Male	1,315
OVC_SERV_DSD	Age/Sex: 18+ Female	2,755
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,070
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,381
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	7,549

Implementing Mechanism Details

Mechanism ID: 16992	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - HIV SA
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: HIVSA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,000,000	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID:	16992		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - HIV SA		
Prime Partner Name:	HIVSA		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,811
PP_PREV_DSD	Total number of people in the target population	5,091
PP_PREV_DSD	Aggregated Age/sex: <15 Male	783
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	672
PP_PREV_DSD	Aggregated Age/sex: <15 Female	198
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	158
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,997
OVC_SERV_DSD	Age/Sex: 18+ Male	780
OVC_SERV_DSD	Age/Sex: 18+ Female	1,560
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,340
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	632
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	2,120
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,437
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,973



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	325
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	175
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,061
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,971
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	11,569
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	12,091

Implementing Mechanism Details

Mechanism ID: 16993	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - The Networking HIV/AIDS Community of South Africa (NACOSA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: NACOSA (Networking AIDS Community of South Africa)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 102,989	
Applied Pipeline Amount: 1,517,811	
Total All Funding Sources and Applied Pipeline Amount: 1,620,800	
Funding Source	Funding Amount
GHP-State	102,989

Cross-Cutting Budget Attribution(s)

Gender: GBV	102,989
Focus Area:	GBV Prevention



Sub Area:	Implementation
-----------	----------------

Budget Code Information

Mechanism ID:	16993		
Mechanism Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - The Networking HIV/AIDS Community of		
Prime Partner Name:	South Africa (NACOSA)		
	NACOSA (Networking AIDS Community of South Africa)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	102,989	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,113
PP_PREV_DSD	Total number of people in the target population	16,240
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,923
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,190
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	758
HTC_TST_DSD	Age/sex: 10-14 Female	94
HTC_TST_DSD	Age/sex: 15-19 Female	664
HTC_TST_DSD	Sum of Age/Sex disaggregates	758
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	80
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	94



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	664
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	94
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	664
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	758
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	6
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	80
HTC_TST_DSD	Service Delivery Point (Community): Other	758
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	45,910
OVC_SERV_DSD	Age/Sex: 18+ Male	3,425
OVC_SERV_DSD	Age/Sex: 18+ Female	6,671
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,096
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	621
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	502
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	116
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,901
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	5,782
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2,823
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,568
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	247
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	491



	and sex: Economic Strengthening Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	333
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	519
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,394
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,379
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	234
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	8,025
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	27,789

Implementing Mechanism Details

Mechanism ID: 17017	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - National Association of Childcare Workers (Roll-out of ISIBINDI model)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: National Association of Childcare Workers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 2,300,000	
Total All Funding Sources and Applied Pipeline Amount: 2,300,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17017 Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - National Association of Childcare Workers Prime Partner Name: (Roll-out of ISIBINDI model) National Association of Childcare Workers			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	25,763
PP_PREV_DSD	Total number of people in the target population	675,460
PP_PREV_DSD	Aggregated Age/sex: <15 Female	9,645
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	16,118
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	31,223
OVC_SERV_DSD	Age/Sex: 18+ Male	861
OVC_SERV_DSD	Age/Sex: 18+ Female	869
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,730
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	826
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	832



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,210
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	7,237
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,396
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,922
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,974
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,545
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	35,527
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	80,738
OVC_SERV_TA	Age/Sex: 18+ Male	4,844
OVC_SERV_TA	Age/Sex: 18+ Female	4,859
OVC_SERV_TA	Sum of Age/Sex disaggregates	9,703

Implementing Mechanism Details

Mechanism ID: 17018	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Innovation for HCTC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: AgriAIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,486,063	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,486,063	
Funding Source	Funding Amount
GHP-State	2,486,063



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17018		
Mechanism Name:	HIV Innovations for Improved Patient Outcomes in South Africa		
Prime Partner Name:	(Innovation for HCTC) AgriAIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	445,819	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	297,212	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	743,032	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	75,529
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,778



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,212
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,778
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,761
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,556
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	67,973
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	75,529
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	3,021
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	8,311
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3,021
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	9,820
HTC_TST_DSD	Service Delivery Point (Community): Index testing	7,553
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	33,989
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	30,212
HTC_TST_DSD	Service Delivery Point (Community): Other	3,775
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,030
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	103
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	811
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	103
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,013
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	206
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,824
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,030
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,810



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	91
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	725
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	91
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	903
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,810
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,651
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,834
TX_PVLS_DSD	Numerator: Indication: Routine	496
TX_PVLS_DSD	Numerator: Indication: Targeted	1,155
TX_PVLS_DSD	Denominator: Indication: Routine	549
TX_PVLS_DSD	Denominator: Indication: Targeted	1,285
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	82
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	659
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	82
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	828
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	92
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	734
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	92
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	916
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,829
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,030
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	732
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	913
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	811
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,013

Implementing Mechanism Details

Mechanism ID: 17019	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM) - Health4Men Program
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Anova Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,990,755	
Applied Pipeline Amount: 731,777	
Total All Funding Sources and Applied Pipeline Amount: 2,722,532	
Funding Source	Funding Amount
GHP-State	1,990,755

Cross-Cutting Budget Attribution(s)

Condom procurement	400,000
Key Populations: MSM and TG	1,590,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG



Budget Code Information

Mechanism ID: 17019		HIV Innovations for Improved Patient Outcomes for Priority Populations	
Mechanism Name:		(Innovative Models for Capacity Building & Support of Scale Up of	
Prime Partner Name:		Effective HIV-related Services for MSM) - Health4Men Program	
		Anova Health Institute	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	472,729	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	646,426	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	41,778	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	83,555	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	554,489	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	41,778	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	14,871



	standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	74,910
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,871
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	74,910
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,821
HTC_TST_DSD	Age/sex: 15-19 Male	1,599
HTC_TST_DSD	Age/sex: 20-24 Male	3,735
HTC_TST_DSD	Age/sex: 25-49 Male	3,733
HTC_TST_DSD	Age/sex: 50+ Male	1,599
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,666
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	286
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	672
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	672
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	286
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,821
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	21,821
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	21,821
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,585
HTC_TST_DSD	Service Delivery Point (Community): Other	11,155
HTC_TST_DSD	Service Delivery Point (Facility): VCT	9,663
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,003



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,195
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,366
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,195
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	785
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	785
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	785
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	18,962
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	18,962
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	569
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	512
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	57
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,864
TX_CURR_DSD	Age/Sex: 15-19 Male	2,380
TX_CURR_DSD	Sum of age/sex disaggregates	2,380
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	15,864
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	15,864
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,864
TX_CURR_DSD	Age/Sex: 20-24 Male	5,553



TX_CURR_DSD	Age/Sex: 25-49 Male	5,552
TX_CURR_DSD	Age/Sex: 50+ Male	2,379
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,749
TX_NEW_DSD	By Age/Sex: 15-19 Male	561
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,314
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,312
TX_NEW_DSD	By Age/Sex: 50+ Male	562
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,749
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,749
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,749
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,848
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,277
TX_PVLS_DSD	Numerator: Indication: Routine	12,848
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	12,848
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,277
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,779
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,339
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,316
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,074
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults)	3,072



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,317
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,399
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,271
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,269
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,399
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,779
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,339

Implementing Mechanism Details

Mechanism ID: 17020	Mechanism Name: Systems Strengthening for
----------------------------	--



	Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Anova Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,269,511	
Applied Pipeline Amount: 4,152,799	
Total All Funding Sources and Applied Pipeline Amount: 6,422,310	
Funding Source	Funding Amount
GHP-State	2,269,511

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	120,000
Motor Vehicles: Leased	100,000

Budget Code Information

Mechanism ID: 17020			
Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes			
Prime Partner Name: Anova Health Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	449,361	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	374,533	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	132,302	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	114,603	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,066,410	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	132,302	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	18
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,367
PMTCT_ART_TA	New on ART	10,864
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	5,855
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	71,367
PMTCT_STAT_TA	Number of new ANC and L&D clients	73,308
PMTCT_STAT_TA	By: Known positives at entry	34,862
PMTCT_STAT_TA	By: Number of new positives identified	36,504
PMTCT_STAT_TA	Sum of Positives Status disaggregates	71,366
PMTCT_STAT_TA	Required only for DREAMS countries - By known	0



	positives: <15	
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	1,063
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	5,363
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	2
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	1,290
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	6,505
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	8
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	2,412
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	12,227
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	39,562
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	263
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	17,348
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	108
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	21,078
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	479
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	10
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	2,347
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	11,873
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	38,425
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	237



PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	34,369
PP_PREV_TA	Total number of people in the target population	702,776
PP_PREV_TA	Aggregated Age/sex: <15 Male	3,438
PP_PREV_TA	Aggregated Age/sex: 15+ Male	13,747
PP_PREV_TA	Aggregated Age/sex: <15 Female	3,438
PP_PREV_TA	Aggregated Age/sex: 15+ Female	13,747
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	244,285
HTC_TST_TA	Age/sex: 10-14 Male	7,537
HTC_TST_TA	Age/sex: 15-19 Male	7,112
HTC_TST_TA	Age/sex: 20-24 Male	7,317
HTC_TST_TA	Age/sex: 25-49 Male	38,544
HTC_TST_TA	Age/sex: 50+ Male	14,263
HTC_TST_TA	Age/sex: 10-14 Female	7,519
HTC_TST_TA	Age/sex: 15-19 Female	7,296
HTC_TST_TA	Age/sex: 20-24 Female	6,883
HTC_TST_TA	Age/sex: 25-49 Female	37,319
HTC_TST_TA	Age/sex: 50+ Female	17,922
HTC_TST_TA	Sum of Age/Sex disaggregates	151,712
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	1,475
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	1,395
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	1,362
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	7,626
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	2,755
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	1,443
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	1,397
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,316
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	7,159
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	3,455



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,086
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	90,620
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,090
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	139,488
HTC_TST_TA	Sum of Aggregated Age/Sex <15	14,176
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	230,108
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	244,284
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	170
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	15,608
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	174
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	23,883
HTC_TST_TA	Test Result by Age: Positive: <1	525
HTC_TST_TA	Test Result by Age: Positive: 1-9	5,244
HTC_TST_TA	Age/sex: <1	2,751
HTC_TST_TA	Age/sex: 1-9	27,309
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,897
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	16,096
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	173,431
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	42,133
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	5,241
HTC_TST_TA	Service Delivery Point (Facility): Index testing	3,491



TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,840
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	13,478
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	682
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,486
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	668
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,993
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9,048
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,422
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,731
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,336
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	468
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	2,506

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	309,201
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	17,215
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	154,543
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	15,710
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	117,258
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	9,462
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,643
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8,911
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	1,026
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	16,616
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	16,616
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	207
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	287,389
TX_CURR_TA	Age/Sex: 15-19 Male	1,131
TX_CURR_TA	Age/Sex: 15-19 Female	2,549
TX_CURR_TA	Sum of Age/Sex disaggregations	3,680
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8,326



TX_CURR_TA	Aggregated Age/Sex: 15+ Male	108,131
TX_CURR_TA	Aggregated Age/Sex: <15 Female	8,298
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	162,654
TX_CURR_TA	Sum of Aggregated Age/Sex <15	16,624
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	270,785
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	287,409
TX_CURR_TA	Age/Sex: <1	681
TX_CURR_TA	Age/Sex: 1-9	3,601
TX_CURR_TA	Age/Sex: 10-14 Male	1,197
TX_CURR_TA	Age/Sex: 10-14 Female	1,267
TX_CURR_TA	Age/Sex: 20-24 Male	1,662
TX_CURR_TA	Age/Sex: 25-49 Male	50,497
TX_CURR_TA	Age/Sex: 50+ Male	17,874
TX_CURR_TA	Age/Sex: 20-24 Female	8,750
TX_CURR_TA	Age/Sex: 25-49 Female	111,173
TX_CURR_TA	Age/Sex: 50+ Female	13,898
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	71,930
TX_NEW_TA	By Age/Sex: 1-9	773
TX_NEW_TA	By Age/Sex: 10-14 Male	155
TX_NEW_TA	By Age/Sex: 15-19 Male	157
TX_NEW_TA	By Age/Sex: 20-24 Male	382
TX_NEW_TA	By Age/Sex: 25-49 Male	14,016
TX_NEW_TA	By Age/Sex: 50+ Male	2,998
TX_NEW_TA	By Age/Sex: 10-14 Female	153
TX_NEW_TA	By Age/Sex: 15-19 Female	679
TX_NEW_TA	By Age/Sex: 20-24 Female	3,844
TX_NEW_TA	By Age/Sex: 25-49 Female	30,520
TX_NEW_TA	By Age/Sex: 50+ Female	3,400
TX_NEW_TA	Sum of Age/Sex disaggregates	56,304
TX_NEW_TA	Aggregated Grouping by Age: <1	48
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	1,770



TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	27,322
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1,807
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	41,027
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	71,926
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	232,788
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	239,363
TX_PVLS_TA	Numerator: Indication: Routine	232,788
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	232,788
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	6,734
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	87,715
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	6,762
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	131,576
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	5,035
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	65,398
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	5,034
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	98,101
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	172,174
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	179,075
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	329
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and	1,741



	children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	555
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	546
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	800
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24,373
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,635
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	612
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,229
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,258
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53,653
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,714
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	353



	have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,848
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	622
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	582
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	856
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,928
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,186
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	650



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,312
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,523
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57,068
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,131
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,915
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64,358
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,955
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96,259
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	760



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38,314
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	789
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72,700

Implementing Mechanism Details

Mechanism ID: 17021	Mechanism Name: Performance for Health through Focused Outputs, Results and Management
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 15,295,364	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,295,364	
Funding Source	Funding Amount
GHP-State	15,295,364



Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Leased	109,360
Gender: Gender Equality	300,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17021		
Mechanism Name:	Performance for Health through Focused Outputs, Results and Management		
Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,573,323	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	2,015,286	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	485,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	971,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,763,755	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	485,750	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,975
PMTCT_ART_TA	New on ART	15,952
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,774
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,975
PMTCT_STAT_TA	Number of new ANC and L&D clients	64,994
PMTCT_STAT_TA	By: Known positives at entry	5,325
PMTCT_STAT_TA	By: Number of new positives identified	12,401



PMTCT_STAT_TA	Sum of Positives Status disaggregates	17,726
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	519
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	1,040
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	1,212
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	2,422
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	1,739
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	3,473
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	12,162
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	3,635
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	8,493
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	1,730
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	3,461
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	12,107
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,437
PP_PREV_TA	Total number of people in the target population	120,155
PP_PREV_TA	Aggregated Age/sex: <15 Male	0
PP_PREV_TA	Aggregated Age/sex: 15+ Male	0
PP_PREV_TA	Aggregated Age/sex: <15 Female	854
PP_PREV_TA	Aggregated Age/sex: 15+ Female	12,583
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,610
HTC_TST_DSD	Age/sex: 10-14 Male	170



HTC_TST_DSD	Age/sex: 15-19 Male	654
HTC_TST_DSD	Age/sex: 20-24 Male	4,286
HTC_TST_DSD	Age/sex: 25-49 Male	10,238
HTC_TST_DSD	Age/sex: 50+ Male	654
HTC_TST_DSD	Age/sex: 10-14 Female	598
HTC_TST_DSD	Age/sex: 15-19 Female	3,667
HTC_TST_DSD	Age/sex: 20-24 Female	5,619
HTC_TST_DSD	Age/sex: 25-49 Female	5,035
HTC_TST_DSD	Age/sex: 50+ Female	1,007
HTC_TST_DSD	Sum of Age/Sex disaggregates	31,928
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	108
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	555
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,235
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	108
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	49
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	426
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	741
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	803
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	160
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	511
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,832
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	939
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,328
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,450
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	31,160
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,610
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	18



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,005
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	61
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,131
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	24
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	682
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	14,977
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	15,870
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,763
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	364,612
HTC_TST_TA	Age/sex: 10-14 Male	580
HTC_TST_TA	Age/sex: 15-19 Male	2,221
HTC_TST_TA	Age/sex: 20-24 Male	6,666
HTC_TST_TA	Age/sex: 25-49 Male	11,107
HTC_TST_TA	Age/sex: 50+ Male	2,221
HTC_TST_TA	Age/sex: 10-14 Female	580
HTC_TST_TA	Age/sex: 15-19 Female	3,421
HTC_TST_TA	Age/sex: 20-24 Female	10,258
HTC_TST_TA	Age/sex: 25-49 Female	17,090
HTC_TST_TA	Age/sex: 50+ Female	3,421
HTC_TST_TA	Sum of Age/Sex disaggregates	57,565
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	21
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	364
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	1,094
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,826



HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	364
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	21
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	545
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,636
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,727
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	545
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,573
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	135,266
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,579
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	208,194
HTC_TST_TA	Sum of Aggregated Age/Sex <15	21,152
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	343,460
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	364,612
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	368
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	22,246
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	368
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	33,185
HTC_TST_TA	Test Result by Age: Positive: 1-9	79
HTC_TST_TA	Age/sex: 1-9	2,315
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	328,155
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	36,457
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,517
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	13,128
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	375
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,752
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	375
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,015
GEND_GBV_DSD	Number of people receiving post-GBV care	272
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0



GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	68
GEND_GBV_DSD	Age/Sex: 20-24 Female	104
GEND_GBV_DSD	Age/Sex: 25-49 Female	0
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	68
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	136
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	136
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	126
GEND_GBV_DSD	Age/Sex: 15-19 Female	100
GEND_GBV_DSD	Age/Sex: 15-19 male	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,209
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	8,002
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	218
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,745
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	218
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	4,028



	TB treatment during the reporting period)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	352,226
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	10,564
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	133,854
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	10,564
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	197,244
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	35,232
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	31,727
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,586
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	26,962
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	3,179
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	17,749
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	17,749
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	267
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,550
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	393
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,106
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	393
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,658
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	786



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,764
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,550
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	359,393
TX_CURR_TA	Aggregated Age/Sex: <15 Male	10,420
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	135,415
TX_CURR_TA	Aggregated Age/Sex: <15 Female	10,420
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	203,138
TX_CURR_TA	Sum of Aggregated Age/Sex <15	20,840
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	338,553
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	359,393
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,612
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	90
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,373
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	90
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,059
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,612
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	93,995
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2,347
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	35,724
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	2,347
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	53,577
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	93,995
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,975
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	12,195
TX_PVLS_DSD	Numerator: Indication: Routine	10,426



TX_PVLS_DSD	Numerator: Indication: Targeted	549
TX_PVLS_DSD	Denominator: Indication: Routine	11,585
TX_PVLS_DSD	Denominator: Indication: Targeted	610
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	318
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,135
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	318
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	6,204
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	354
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4,595
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	354
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	6,892
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	291,109
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	323,455
TX_PVLS_TA	Numerator: Indication: Routine	276,555
TX_PVLS_TA	Numerator: Indication: Targeted	14,554
TX_PVLS_TA	Denominator: Indication: Routine	307,281
TX_PVLS_TA	Denominator: Indication: Targeted	16,173
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	8,441
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	109,684
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	8,441
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	164,543
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	9,381
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	121,881
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	9,381
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	182,812
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,541
TX_RET_DSD	Total number of adults and children who initiated ART	6,959



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,465
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,696
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,622
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,933



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	227,063
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	241,547
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,579
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85,560
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,579
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	128,345
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,003
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91,015
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,003
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	136,526



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 17022	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Developing & Institutionalizing an Innovative Capacity Building Model to Support SA Government Priorities & to Improve HIV/TB Health Outcomes for Priority Populations - “South to South Stellenbosch”)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: The South-to-South Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,328,779	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,328,779	
Funding Source	Funding Amount
GHP-State	3,328,779

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17022



Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa			
Prime Partner Name: (Developing & Institutionalizing an Innovative Capacity Building Model to Support SA Government Priorities & to Improve HIV/TB Health Outcomes for Priority Populations - “South to South Stellenbosch”) The South-to-South Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,330,145	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	998,634	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	341
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	44
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,761



PMTCT_ART_TA	New on ART	2,202
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	264
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,761
PMTCT_STAT_TA	Number of new ANC and L&D clients	13,028
PMTCT_STAT_TA	By: Known positives at entry	1,290
PMTCT_STAT_TA	By: Number of new positives identified	11,469
PMTCT_STAT_TA	Sum of Positives Status disaggregates	12,759
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,474
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,474
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	27
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	4

Implementing Mechanism Details

Mechanism ID: 17023	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Broadreach	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 19,952,015	
Applied Pipeline Amount: 2,099,861	
Total All Funding Sources and Applied Pipeline Amount: 22,051,876	
Funding Source	Funding Amount
GHP-State	19,952,015



Cross-Cutting Budget Attribution(s)

Human Resources for Health	4,193,999
Motor Vehicles: Leased	600,000

Budget Code Information

Mechanism ID: 17023			
Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes			
Prime Partner Name: Broadreach			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,580,136	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,935,566	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	730,378	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	960,756	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	12,014,801	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	730,378	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,093
PMTCT_ART_TA	New on ART	7,264
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	10,905
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,093
PMTCT_STAT_TA	Number of new ANC and L&D clients	84,793
PMTCT_STAT_TA	By: Known positives at entry	33,244
PMTCT_STAT_TA	By: Number of new positives identified	49,849
PMTCT_STAT_TA	Sum of Positives Status disaggregates	83,093
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	378,711
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	22,722
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	128,767
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	34,074
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	193,148
HTC_TST_TA	Sum of Aggregated Age/Sex <15	56,796
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	321,915
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	378,711
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	2,863

HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	16,221
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	4,306
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	24,327
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	4,366
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	197,944
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	53,140
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	123,261
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	24,786
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	26,084
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,494
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,430
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,233
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,629
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	13,382
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	14,867
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	811

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,543
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,195
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,833
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	531,479
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	31,889
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	180,707
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	47,834
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	271,049
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	13,241
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	11,961
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,190
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	10,156
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	616
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	18,169
PMTCT_EID_TA	Sum of Infant Age disaggregates	18,169
PMTCT_EID_TA	Number of infants with a positive virological test result	165



	within 2 months of birth	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	518,575
TX_CURR_TA	Aggregated Age/Sex: <15 Male	31,122
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	176,311
TX_CURR_TA	Aggregated Age/Sex: <15 Female	46,662
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	264,480
TX_CURR_TA	Sum of Aggregated Age/Sex <15	77,784
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	440,791
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	518,575
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	95,124
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	5,712
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	32,336
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	8,560
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	48,516
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	95,124
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	420,038
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	466,714
TX_PVLS_TA	Numerator: Indication: Routine	378,027
TX_PVLS_TA	Numerator: Indication: Targeted	42,011
TX_PVLS_TA	Denominator: Indication: Routine	420,069
TX_PVLS_TA	Denominator: Indication: Targeted	46,672
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	25,213
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	142,806
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	37,791
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	214,228
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	27,996



TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	158,676
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	42,008
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	238,041
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	487,464
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	599,426
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29,245
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165,734
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	43,868
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248,617
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,966
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	203,804
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	53,946



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	305,710

Implementing Mechanism Details

Mechanism ID: 17024	Mechanism Name: Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Professional Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 317,040	
Applied Pipeline Amount: 2,056,234	
Total All Funding Sources and Applied Pipeline Amount: 2,373,274	
Funding Source	Funding Amount
GHP-State	317,040

Cross-Cutting Budget Attribution(s)

Human Resources for Health	120,000
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17024		
Mechanism Name:	Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid)		
Prime Partner Name:	Foundation for Professional Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	117,040	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,510
PMTCT_ART_TA	New on ART	108
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	161
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,510
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,540
PMTCT_STAT_TA	By: Known positives at entry	606
PMTCT_STAT_TA	By: Number of new positives identified	905
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,511
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,049
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	363
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,055
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	545
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,083
HTC_TST_TA	Sum of Aggregated Age/Sex <15	908
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	5,138
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	6,046
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	43
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	257



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	70
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	388
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	605
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	5,444
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	293
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	307
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	101
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	148
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	158
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	176
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	7

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	54
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	79
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,772
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	4
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	32
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	8
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	48
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	96
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	85
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	8
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	73
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	3
PMTCT_EID_TA	By infants who received a virologic test within 2 months	295



	of birth	
PMTCT_EID_TA	Sum of Infant Age disaggregates	295
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,610
TX_CURR_TA	Aggregated Age/Sex: <15 Male	276
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,567
TX_CURR_TA	Aggregated Age/Sex: <15 Female	414
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,350
TX_CURR_TA	Sum of Aggregated Age/Sex <15	690
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,917
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,607
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,206
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	72
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	401
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	108
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	614
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,195
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,735
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,148
TX_PVLS_TA	Numerator: Indication: Routine	3,359
TX_PVLS_TA	Numerator: Indication: Targeted	373
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	224
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,269
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	336
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	1,905



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,542
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,707
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	152
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	865
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	230
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,299
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	50



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 17025	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (INROADS: Innovations Research on HIV/AIDS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Health Consortium, Health Economics and Epidemiology Research Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,000,000	
Funding Source	Funding Amount
GHP-State	3,000,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17025		
Mechanism Name:	HIV Innovations for Improved Patient Outcomes for Priority Populations (INROADS: Innovations Research on HIV/AIDS)		
Prime Partner Name:	Wits Health Consortium, Health Economics and Epidemiology Research Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17026	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Developing the Capacity of the South African Government to Achieve the eMTCT Action Framework Goals)
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Mothers to Mothers (M2M)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,348,824	
Applied Pipeline Amount: 957,690	
Total All Funding Sources and Applied Pipeline Amount: 2,306,514	
Funding Source	Funding Amount
GHP-State	1,348,824

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Human Resources for Health	1,000,000

Budget Code Information

Mechanism ID:	17026		
Mechanism Name:	HIV Innovations for Improved Patient Outcomes in South Africa		
Prime Partner Name:	(Developing the Capacity of the South African Government to Achieve the eMTCT Action Framework Goals)		
	Mothers to Mothers (M2M)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,348,824	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,717
PMTCT_ART_TA	New on ART	2,935
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	324
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	575
PMTCT_STAT_DSD	Number of new ANC and L&D clients	587
PMTCT_STAT_DSD	By: Known positives at entry	50
PMTCT_STAT_DSD	By: Number of new positives identified	48
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	98
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	12



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	43
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	144
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	400
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	34
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	33
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	43
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	140
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	392
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,717
PMTCT_STAT_TA	Number of new ANC and L&D clients	18,355
PMTCT_STAT_TA	By: Known positives at entry	1,392
PMTCT_STAT_TA	By: Number of new positives identified	1,370
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,762
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	177
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	577
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	79
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	259
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	1,299



PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	4,287
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	11,983
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	1,646
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	743
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	1,116
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	3,707
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	10,387
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	316
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	36,248
PP_PREV_TA	Total number of people in the target population	36,248
PP_PREV_TA	Aggregated Age/sex: 15+ Female	36,248
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	54,766
HTC_TST_TA	Age/sex: 15-19 Female	3,873
HTC_TST_TA	Age/sex: 20-24 Female	13,363
HTC_TST_TA	Age/sex: 25-49 Female	37,350
HTC_TST_TA	Age/sex: 50+ Female	0
HTC_TST_TA	Sum of Age/Sex disaggregates	54,586
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	690
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	2,397
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	6,350
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	54,765
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	54,765
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	54,765
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	9,311



	Female	
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	290
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	305
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	290
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	156
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	174
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	156
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during	5,912



	the reporting period.	
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	5,912
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	0
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	169
PMTCT_EID_DSD	Sum of Infant Age disaggregates	169
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	3,233
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,233
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,812
TX_CURR_DSD	Age/Sex: 15-19 Female	1,244
TX_CURR_DSD	Sum of age/sex disaggregates	1,244
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,812
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,812
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,812
TX_CURR_DSD	Age/Sex: 20-24 Female	4,102
TX_CURR_DSD	Age/Sex: 25-49 Female	11,466
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	50,313
TX_CURR_TA	Age/Sex: 15-19 Male	0
TX_CURR_TA	Age/Sex: 15-19 Female	3,722
TX_CURR_TA	Sum of Age/Sex disaggregations	3,722
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	50,313
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	50,313



TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	50,313
TX_CURR_TA	Age/Sex: 20-24 Male	0
TX_CURR_TA	Age/Sex: 25-49 Male	0
TX_CURR_TA	Age/Sex: 20-24 Female	12,276
TX_CURR_TA	Age/Sex: 25-49 Female	34,314
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,997
TX_NEW_DSD	By Age/Sex: 15-19 Female	357
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,617
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,518
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,492
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,830
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,830
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,959
TX_NEW_TA	By Age/Sex: 15-19 Female	1,070
TX_NEW_TA	By Age/Sex: 20-24 Female	3,527
TX_NEW_TA	By Age/Sex: 25-49 Female	9,860
TX_NEW_TA	Sum of Age/Sex disaggregates	14,457
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	14,457
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	14,457
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	0
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	42,469



	laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	47,182
TX_PVLS_TA	Numerator: Indication: Routine	42,469
TX_PVLS_TA	Denominator: Indication: Routine	43,970
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	42,469
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	47,182
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	0



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,270
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	34,060
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,648
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,435
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,187
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,087
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	6,884



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,237
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26,716
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,208

Implementing Mechanism Details

Mechanism ID: 17027	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Supporting the SA Government to Develop, Implement and Evaluate a National Sex Worker and Male Client Plan)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Reproductive Health& HIV Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,439,732	
Applied Pipeline Amount: 375,776	
Total All Funding Sources and Applied Pipeline Amount: 1,815,508	
Funding Source	Funding Amount
GHP-State	1,439,732

Cross-Cutting Budget Attribution(s)



Condom programming	404,699
Human Resources for Health	330,954
Key Populations: FSW	65,559
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	585,048
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Motor Vehicles: Purchased	87,500

Budget Code Information

Mechanism ID: 17027 Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations Prime Partner Name: (Supporting the SA Government to Develop, Implement and Evaluate a National Sex Worker and Male Client Plan) Wits Reproductive Health& HIV Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	267,887	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	289,180	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	43,922	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	12,067	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	632,754	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	43,922	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	835
PrEP_NEW_DSD	Female 20-24	835
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,202
PP_PREV_DSD	Total number of people in the target population	936,690
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,202
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,860



KP_PREV_DSD	Total estimated number of key population in the catchment area	37,334
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,860
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	8,960
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	28,374
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,253
HTC_TST_DSD	Age/sex: 10-14 Male	0
HTC_TST_DSD	Age/sex: 15-19 Male	225
HTC_TST_DSD	Age/sex: 20-24 Male	2,327
HTC_TST_DSD	Age/sex: 25-49 Male	5,608
HTC_TST_DSD	Age/sex: 50+ Male	49
HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD	Age/sex: 15-19 Female	98
HTC_TST_DSD	Age/sex: 20-24 Female	1,809
HTC_TST_DSD	Age/sex: 25-49 Female	4,475
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	14,591
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	388
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	560
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	183
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	448
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,423
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,830
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	19,253
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,253
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,249
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	942
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	13,669
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	5,584
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,160
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	36
TX_CURR_DSD	Sum of age/sex disaggregates	36
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	836
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,324
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,160



TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,160
TX_CURR_DSD	Age/Sex: 20-24 Male	86
TX_CURR_DSD	Age/Sex: 25-49 Male	308
TX_CURR_DSD	Age/Sex: 50+ Male	32
TX_CURR_DSD	Age/Sex: 20-24 Female	130
TX_CURR_DSD	Age/Sex: 25-49 Female	460
TX_CURR_DSD	Age/Sex: 50+ Female	28
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,488
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	24
TX_NEW_DSD	By Age/Sex: 25-49 Male	136
TX_NEW_DSD	By Age/Sex: 50+ Male	32
TX_NEW_DSD	By Age/Sex: 15-19 Female	14
TX_NEW_DSD	By Age/Sex: 20-24 Female	40
TX_NEW_DSD	By Age/Sex: 25-49 Female	472
TX_NEW_DSD	By Age/Sex: 50+ Female	24
TX_NEW_DSD	Sum of Age/Sex disaggregates	744
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	477
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,011
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,488
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,752
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,944
TX_PVLS_DSD	Numerator: Indication: Routine	1,752
TX_PVLS_DSD	Denominator: Indication: Routine	1,944
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	704
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,048
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	776



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,168
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,032
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,160
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	352
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	508
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of	12



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	376
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	540
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months	0



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	824
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,208
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	876
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,284

Implementing Mechanism Details

Mechanism ID: 17028	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Adolescent Friendly Services for Prenatally & Behaviorally HIV Infected Adolescents)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Reproductive Health& HIV Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 2,153,253	
Total All Funding Sources and Applied Pipeline Amount: 2,153,253	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17028 Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations Prime Partner Name: (Adolescent Friendly Services for Prenatally & Behaviorally HIV Infected Adolescents) Wits Reproductive Health& HIV Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,476
PP_PREV_TA	Total number of people in the target population	216,607
PP_PREV_TA	Aggregated Age/sex: 15+ Female	13,476
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,650
HTC_TST_DSD	Age/sex: 10-14 Male	12
HTC_TST_DSD	Age/sex: 15-19 Male	92
HTC_TST_DSD	Age/sex: 20-24 Male	176
HTC_TST_DSD	Age/sex: 25-49 Male	0
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	28
HTC_TST_DSD	Age/sex: 15-19 Female	456
HTC_TST_DSD	Age/sex: 20-24 Female	886
HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,650
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	8
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	36
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	72
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	268
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	28
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,342
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	40
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,610
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,650
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	10
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	22
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	108
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,650
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,750
HTC_TST_TA	Age/sex: 10-14 Male	78
HTC_TST_TA	Age/sex: 15-19 Male	598
HTC_TST_TA	Age/sex: 20-24 Male	1,144
HTC_TST_TA	Age/sex: 25-49 Male	0
HTC_TST_TA	Age/sex: 50+ Male	0
HTC_TST_TA	Age/sex: 10-14 Female	182



HTC_TST_TA	Age/sex: 15-19 Female	2,964
HTC_TST_TA	Age/sex: 20-24 Female	5,759
HTC_TST_TA	Age/sex: 25-49 Female	0
HTC_TST_TA	Age/sex: 50+ Female	0
HTC_TST_TA	Sum of Age/Sex disaggregates	10,725
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	65
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	52
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	91
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	13
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	234
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	468
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	384
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,819
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	811
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,736
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,195
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	23,555
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	24,750
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	150
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	381
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	64
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	1,501



	Female	
HTC_TST_TA	Test Result by Age: Positive: <1	0
HTC_TST_TA	Test Result by Age: Positive: 1-9	0
HTC_TST_TA	Age/sex: <1	0
HTC_TST_TA	Age/sex: 1-9	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	24,750
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,568
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,650
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	276
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	402
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	296
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	594
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	23,520
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	24,750
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,644
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,152
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	3,063



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10,661
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	892
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	990
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	158
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	228
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	168
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	338
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	13,380
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	14,850
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1,503



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,083
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,738
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,056
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	990
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	80
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	156
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	80
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	674
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	148
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	148
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	148
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	14,850
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,557
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	2,170
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,523
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	9,600
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	2,072
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent:	2,072



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	2,072
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	488
TX_CURR_DSD	Age/Sex: 15-19 Male	32
TX_CURR_DSD	Age/Sex: 15-19 Female	96
TX_CURR_DSD	Sum of age/sex disaggregates	128
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	58
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	96
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	54
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	280
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	112
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	376
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	488
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	58
TX_CURR_DSD	Age/Sex: 10-14 Female	54
TX_CURR_DSD	Age/Sex: 20-24 Male	64
TX_CURR_DSD	Age/Sex: 25-49 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	184
TX_CURR_DSD	Age/Sex: 25-49 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,320
TX_CURR_TA	Age/Sex: 15-19 Male	208
TX_CURR_TA	Age/Sex: 15-19 Female	624
TX_CURR_TA	Sum of Age/Sex disaggregations	832
TX_CURR_TA	Aggregated Age/Sex: <15 Male	887
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,151



TX_CURR_TA	Aggregated Age/Sex: <15 Female	827
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,455
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,714
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,606
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,320
TX_CURR_TA	Age/Sex: <1	0
TX_CURR_TA	Age/Sex: 1-9	0
TX_CURR_TA	Age/Sex: 10-14 Male	377
TX_CURR_TA	Age/Sex: 10-14 Female	351
TX_CURR_TA	Age/Sex: 20-24 Male	416
TX_CURR_TA	Age/Sex: 25-49 Male	0
TX_CURR_TA	Age/Sex: 50+ Male	0
TX_CURR_TA	Age/Sex: 20-24 Female	1,196
TX_CURR_TA	Age/Sex: 25-49 Female	0
TX_CURR_TA	Age/Sex: 50+ Female	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	188
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	18
TX_NEW_DSD	By Age/Sex: 25-49 Male	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	54
TX_NEW_DSD	By Age/Sex: 20-24 Female	106
TX_NEW_DSD	By Age/Sex: 25-49 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	188
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	26



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	160
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	188
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,820
TX_NEW_TA	By Age/Sex: 1-9	0
TX_NEW_TA	By Age/Sex: 10-14 Male	0
TX_NEW_TA	By Age/Sex: 15-19 Male	52
TX_NEW_TA	By Age/Sex: 20-24 Male	117
TX_NEW_TA	By Age/Sex: 25-49 Male	0
TX_NEW_TA	By Age/Sex: 50+ Male	0
TX_NEW_TA	By Age/Sex: 10-14 Female	13
TX_NEW_TA	By Age/Sex: 15-19 Female	351
TX_NEW_TA	By Age/Sex: 20-24 Female	689
TX_NEW_TA	By Age/Sex: 25-49 Female	0
TX_NEW_TA	By Age/Sex: 50+ Female	0
TX_NEW_TA	Sum of Age/Sex disaggregates	1,222
TX_NEW_TA	Aggregated Grouping by Age: <1	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	32
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	262
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	30
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	2,496
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,820
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	396
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	440
TX_PVLS_DSD	Numerator: Indication: Routine	396
TX_PVLS_DSD	Denominator: Indication: Routine	440
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	10



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	60
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	322
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	52
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	86
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	50
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	252
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,940
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,600
TX_PVLS_TA	Numerator: Indication: Routine	5,940
TX_PVLS_TA	Denominator: Indication: Routine	6,600
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	286
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	747
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	400
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	4,507
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	316
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	920
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	451
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	4,913
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	440
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	488
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	56
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	166
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	0



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	54



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	184
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	252
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	56



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	282
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,820
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,320
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	338
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults	195



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	364
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	325
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	559
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,079
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	0



	lost to follow-up)	
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	377
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	221
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	416
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	351
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	611



TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,196
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	842
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,063
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	775
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,140
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	874
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,151



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	827
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,468

Implementing Mechanism Details

Mechanism ID: 17029	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Innovation Clinic)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Witkoppen Health & Welfare Centre (WHWC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,370,777	
Applied Pipeline Amount: 437,759	
Total All Funding Sources and Applied Pipeline Amount: 1,808,536	
Funding Source	Funding Amount
GHP-State	1,370,777

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17029		
Mechanism Name:	HIV Innovations for Improved Patient Outcomes in South Africa		
Prime Partner Name:	(Innovation Clinic) Witkoppen Health & Welfare Centre (WHWC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	261,707	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	180,854	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	71,547	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	80,854	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	704,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	71,547	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,175
PMTCT_ART_DSD	New on ART	606
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	252
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,175
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,325
PMTCT_STAT_DSD	By: Known positives at entry	934
PMTCT_STAT_DSD	By: Number of new positives identified	2,241
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,175
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	168
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	633
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	70
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	264
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	249
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	939
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	2,137
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	0



	50+	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	600
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,440
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	238
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	897
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	2,040
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,224
HTC_TST_DSD	Age/sex: 10-14 Male	139
HTC_TST_DSD	Age/sex: 15-19 Male	451
HTC_TST_DSD	Age/sex: 20-24 Male	1,589
HTC_TST_DSD	Age/sex: 25-49 Male	6,353
HTC_TST_DSD	Age/sex: 50+ Male	1,297
HTC_TST_DSD	Age/sex: 10-14 Female	89
HTC_TST_DSD	Age/sex: 15-19 Female	288
HTC_TST_DSD	Age/sex: 20-24 Female	1,015
HTC_TST_DSD	Age/sex: 25-49 Female	4,059
HTC_TST_DSD	Age/sex: 50+ Female	828
HTC_TST_DSD	Sum of Age/Sex disaggregates	16,108
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	11
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	36
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	124
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	494
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	101



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	66
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	231
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	926
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	189
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	139
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,691
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,204
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,190
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,343
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,881
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,224
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	199
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	754
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	199
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,431
HTC_TST_DSD	Test Result by Age: Positive: <1	197
HTC_TST_DSD	Test Result by Age: Positive: 1-9	188
HTC_TST_DSD	Age/sex: <1	1,445
HTC_TST_DSD	Age/sex: 1-9	1,671
HTC_TST_DSD	Service Delivery Point (Community): Index testing	250
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	230
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	3,845
HTC_TST_DSD	Service Delivery Point (Community): Other	481



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,507
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,971
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,325
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	615
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	494
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	884
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	319
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	544
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	317
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	567
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	122



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	428
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	15,380
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	103
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,291
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	365
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	11,621
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	615
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	554
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	554
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	876
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	876
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	22
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,297
TX_CURR_DSD	Age/Sex: 15-19 Male	18
TX_CURR_DSD	Age/Sex: 15-19 Female	83
TX_CURR_DSD	Sum of age/sex disaggregates	101



TX_CURR_DSD	Aggregated Age/Sex: <15 Male	214
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,840
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	255
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,988
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	469
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,828
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	8,297
TX_CURR_DSD	Age/Sex: <1	60
TX_CURR_DSD	Age/Sex: <1-9	133
TX_CURR_DSD	Age/Sex: 10-14 Male	28
TX_CURR_DSD	Age/Sex: 10-14 Female	32
TX_CURR_DSD	Age/Sex: 20-24 Male	55
TX_CURR_DSD	Age/Sex: 25-49 Male	2,663
TX_CURR_DSD	Age/Sex: 50+ Male	220
TX_CURR_DSD	Age/Sex: 20-24 Female	560
TX_CURR_DSD	Age/Sex: 25-49 Female	4,092
TX_CURR_DSD	Age/Sex: 50+ Female	353
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,212
TX_NEW_DSD	By Age/Sex: <1	16
TX_NEW_DSD	By Age/Sex: 1-9	35
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	15
TX_NEW_DSD	By Age/Sex: 25-49 Male	710
TX_NEW_DSD	By Age/Sex: 50+ Male	59
TX_NEW_DSD	By Age/Sex: 10-14 Female	9
TX_NEW_DSD	By Age/Sex: 15-19 Female	22
TX_NEW_DSD	By Age/Sex: 20-24 Female	149
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,091
TX_NEW_DSD	By Age/Sex: 50+ Female	94
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,161



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	29
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	788
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,357
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,212
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	6,721
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,468
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	174
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,301
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	207
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	4,039
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	193
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	2,556
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	230
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	4,489
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,006
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,262
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	13



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,285
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	270
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,976
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	171
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	68



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,368
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	113
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	42



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	288
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,104
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	181
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,371
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	123
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,409
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	110
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	1,459



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,562

Implementing Mechanism Details

Mechanism ID: 17033	Mechanism Name: Medical Research Council (CDC GH1150)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 2,300,000	
Total All Funding Sources and Applied Pipeline Amount: 2,300,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17033			
Mechanism Name: Medical Research Council (CDC GH1150)			
Prime Partner Name: Medical Research Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17036	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Professional Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 19,098,335	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 19,098,335	
Funding Source	Funding Amount
GHP-State	19,098,335

Cross-Cutting Budget Attribution(s)

Human Resources for Health	120,000
Gender: GBV	80,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17036		
Mechanism Name:	Systems Strengthening for Better HIV/TB Patient Outcomes		
Prime Partner Name:	Foundation for Professional Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,241,153	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,488,348	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	578,514	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,157,028	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	11,054,778	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	578,514	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	98,298
PMTCT_ART_DSD	New on ART	6,223
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8,825
PMTCT_ART_TA	New on ART	0
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	0



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	98,298
PMTCT_STAT_DSD	Number of new ANC and L&D clients	100,282
PMTCT_STAT_DSD	By: Known positives at entry	39,317
PMTCT_STAT_DSD	By: Number of new positives identified	58,913
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	98,230
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	203
PMTCT_STAT_TA	Number of new ANC and L&D clients	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	657,598
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	39,453
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	223,132
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	59,174
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	330,122
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	98,627
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	553,254
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	651,881
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	5,010
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	28,203
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	9,180
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	42,220
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	15,929
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	387,778



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	74,421
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	174,293
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	35
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	1,927
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	578
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	15,175
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	16,025
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	915
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,229
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,357
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,732
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	8,401
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	9,241



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,089
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,200
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	691
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,405
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	506,060



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	607
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,432
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	906
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,140
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	10,286
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,253
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	922
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	7,866
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	462
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	0
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	104
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	3
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	14,879
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	62
PMTCT_EID_DSD	Sum of Infant Age disaggregates	14,941
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	128



PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	10
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	16
PMTCT_EID_TA	Sum of Infant Age disaggregates	16
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	466,368
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	27,982
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	158,510
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	41,968
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	237,873
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	69,950
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	396,383
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	466,333
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	351
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	351
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	351
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	204,313
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	12,532
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	67,384
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	18,116
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	102,651
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	200,683
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	37
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	37
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	379,114
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	422,305



	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	330,936
TX_PVLS_DSD	Numerator: Indication: Targeted	38,313
TX_PVLS_DSD	Denominator: Indication: Routine	61,970
TX_PVLS_DSD	Denominator: Indication: Targeted	6,885
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	23,196
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	129,789
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	34,620
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	192,661
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,857
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	21,861
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,791
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	32,796
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	0
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	499
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	499
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	241,089
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	261,785
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,457
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81,935
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	21,683

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	122,838
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,516
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,264
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,773
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,398
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	13



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76

Implementing Mechanism Details

Mechanism ID: 17037	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Reproductive Health& HIV Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,466,232	
Applied Pipeline Amount: 4,439,717	
Total All Funding Sources and Applied Pipeline Amount: 6,905,949	
Funding Source	Funding Amount
GHP-State	2,466,232

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	7,715
Gender: Gender Equality	68,568
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Sub Area:	Operation Research
Human Resources for Health	799,932
Condom programming	36,711

Budget Code Information

Mechanism ID: 17037			
Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes			
Prime Partner Name: Wits Reproductive Health& HIV Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	428,163	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	311,707	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	65,084	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	130,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,466,028	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	65,084	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,708
PMTCT_ART_DSD	New on ART	255
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	594
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,766
PMTCT_ART_TA	New on ART	2,197
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	5,124
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,708
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,694
PMTCT_STAT_DSD	By: Known positives at entry	65
PMTCT_STAT_DSD	By: Number of new positives identified	210
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	275
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	63



	known positives: 25-49	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	204
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	159
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	2,547
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,766
PMTCT_STAT_TA	Number of new ANC and L&D clients	23,960
PMTCT_STAT_TA	By: Known positives at entry	1,674
PMTCT_STAT_TA	By: Number of new positives identified	2,069
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,743
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	27
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	48
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	491



PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	1,051
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	10
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	672
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	10,725
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	49,774
HTC_TST_DSD	Age/sex: 10-14 Male	35
HTC_TST_DSD	Age/sex: 15-19 Male	249
HTC_TST_DSD	Age/sex: 20-24 Male	498
HTC_TST_DSD	Age/sex: 25-49 Male	11,411
HTC_TST_DSD	Age/sex: 50+ Male	6,471
HTC_TST_DSD	Age/sex: 10-14 Female	35
HTC_TST_DSD	Age/sex: 15-19 Female	996
HTC_TST_DSD	Age/sex: 20-24 Female	2,986
HTC_TST_DSD	Age/sex: 25-49 Female	14,898
HTC_TST_DSD	Age/sex: 50+ Female	9,955
HTC_TST_DSD	Sum of Age/Sex disaggregates	47,534
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	48
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,189
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	712
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	28



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	332
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,273
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,095
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,155
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,630
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,155
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,834
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,310
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	47,464
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	49,774
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	25
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,964
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	25
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,727
HTC_TST_DSD	Test Result by Age: Positive: <1	35
HTC_TST_DSD	Test Result by Age: Positive: 1-9	5
HTC_TST_DSD	Age/sex: <1	1,742
HTC_TST_DSD	Age/sex: 1-9	498
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,940
HTC_TST_DSD	Service Delivery Point (Facility): VCT	28,666
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	18,168
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95,415
HTC_TST_TA	Age/sex: 10-14 Male	30



HTC_TST_TA	Age/sex: 15-19 Male	217
HTC_TST_TA	Age/sex: 20-24 Male	434
HTC_TST_TA	Age/sex: 25-49 Male	9,863
HTC_TST_TA	Age/sex: 50+ Male	5,599
HTC_TST_TA	Age/sex: 10-14 Female	30
HTC_TST_TA	Age/sex: 15-19 Female	862
HTC_TST_TA	Age/sex: 20-24 Female	2,583
HTC_TST_TA	Age/sex: 25-49 Female	12,890
HTC_TST_TA	Age/sex: 50+ Female	8,613
HTC_TST_TA	Sum of Age/Sex disaggregates	41,121
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	12
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	40
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,023
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	616
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	4
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	23
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	287
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	1,114
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	947
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,886
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	36,454
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,225
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	54,850
HTC_TST_TA	Sum of Aggregated Age/Sex <15	4,111
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	91,304
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	95,415
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	52



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,894
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	70
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,275
HTC_TST_TA	Test Result by Age: Positive: <1	30
HTC_TST_TA	Test Result by Age: Positive: 1-9	4
HTC_TST_TA	Age/sex: <1	1,505
HTC_TST_TA	Age/sex: 1-9	434
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,400
HTC_TST_TA	Service Delivery Point (Facility): VCT	85,431
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	7,584
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,867
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,004
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,186
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,401
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	14,136
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	14,820



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	596
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,533
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	629
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,378
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	917
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,640
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	402
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	423
TB_ART_TA	The number of registered new and relapse TB cases	6,580

	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	8,328
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	324
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,366
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	325
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,565
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	64,278
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,214
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	23,140
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,214
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	34,710
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	9,642
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,642
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	9,642
TB_SCREENDX_TA	The number of PLHIV who were screened for TB	171,510



	symptoms at the last clinical visit at a HIV facility during the reporting period.	
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	8,568
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	61,739
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	8,569
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	92,634
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	25,724
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	25,724
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	25,724
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	153
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	696
PMTCT_EID_DSD	Sum of Infant Age disaggregates	849
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	14
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,379
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	5,925
PMTCT_EID_TA	Sum of Infant Age disaggregates	7,304
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	148
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	78,482
TX_CURR_DSD	Age/Sex: 15-19 Male	32
TX_CURR_DSD	Age/Sex: 15-19 Female	96



TX_CURR_DSD	Sum of age/sex disaggregates	128
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,016
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	28,984
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,018
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	45,464
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,034
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	74,448
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	78,482
TX_CURR_DSD	Age/Sex: <1	2,747
TX_CURR_DSD	Age/Sex: <1-9	1,177
TX_CURR_DSD	Age/Sex: 10-14 Male	54
TX_CURR_DSD	Age/Sex: 10-14 Female	56
TX_CURR_DSD	Age/Sex: 20-24 Male	64
TX_CURR_DSD	Age/Sex: 25-49 Male	15,546
TX_CURR_DSD	Age/Sex: 50+ Male	13,342
TX_CURR_DSD	Age/Sex: 20-24 Female	184
TX_CURR_DSD	Age/Sex: 25-49 Female	29,488
TX_CURR_DSD	Age/Sex: 50+ Female	15,696
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	140,273
TX_CURR_TA	Age/Sex: 15-19 Male	256
TX_CURR_TA	Age/Sex: 15-19 Female	768
TX_CURR_TA	Sum of Age/Sex disaggregations	1,024
TX_CURR_TA	Aggregated Age/Sex: <15 Male	6,284
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	45,923
TX_CURR_TA	Aggregated Age/Sex: <15 Female	6,367
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	81,699
TX_CURR_TA	Sum of Aggregated Age/Sex <15	12,651
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	127,622
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	140,273
TX_CURR_TA	Age/Sex: <1	2,597
TX_CURR_TA	Age/Sex: 1-9	1,113



TX_CURR_TA	Age/Sex: 10-14 Male	432
TX_CURR_TA	Age/Sex: 10-14 Female	448
TX_CURR_TA	Age/Sex: 20-24 Male	512
TX_CURR_TA	Age/Sex: 25-49 Male	13,630
TX_CURR_TA	Age/Sex: 50+ Male	12,609
TX_CURR_TA	Age/Sex: 20-24 Female	1,472
TX_CURR_TA	Age/Sex: 25-49 Female	25,502
TX_CURR_TA	Age/Sex: 50+ Female	14,836
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	20,922
TX_NEW_DSD	By Age/Sex: <1	732
TX_NEW_DSD	By Age/Sex: 1-9	313
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	18
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,158
TX_NEW_DSD	By Age/Sex: 50+ Male	3,557
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	54
TX_NEW_DSD	By Age/Sex: 20-24 Female	106
TX_NEW_DSD	By Age/Sex: 25-49 Female	7,789
TX_NEW_DSD	By Age/Sex: 50+ Female	4,185
TX_NEW_DSD	Sum of Age/Sex disaggregates	19,877
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	523
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,741
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	525
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,133
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	20,922
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	33,464
TX_NEW_TA	By Age/Sex: 1-9	297
TX_NEW_TA	By Age/Sex: 10-14 Male	0



TX_NEW_TA	By Age/Sex: 15-19 Male	64
TX_NEW_TA	By Age/Sex: 20-24 Male	144
TX_NEW_TA	By Age/Sex: 25-49 Male	3,740
TX_NEW_TA	By Age/Sex: 50+ Male	3,362
TX_NEW_TA	By Age/Sex: 10-14 Female	16
TX_NEW_TA	By Age/Sex: 15-19 Female	432
TX_NEW_TA	By Age/Sex: 20-24 Female	822
TX_NEW_TA	By Age/Sex: 25-49 Female	6,250
TX_NEW_TA	By Age/Sex: 50+ Female	3,955
TX_NEW_TA	Sum of Age/Sex disaggregates	18,785
TX_NEW_TA	Aggregated Grouping by Age: <1	692
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	1,141
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	11,526
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1,213
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	19,584
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	33,464
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	63,570
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	70,634
TX_PVLS_DSD	Numerator: Indication: Routine	63,570
TX_PVLS_DSD	Denominator: Indication: Routine	70,634
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,179
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	22,885
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,179
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	34,327
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,532
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	25,427
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,532



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	38,143
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	113,624
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	126,244
TX_PVLS_TA	Numerator: Indication: Routine	113,624
TX_PVLS_TA	Denominator: Indication: Routine	126,244
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	5,682
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	40,902
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	5,682
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	61,358
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	6,311
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	45,446
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	6,311
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	68,176
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	37,890
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	40,308
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,326
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	568
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	52
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults	12



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,440
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,441
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	166
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,097
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,578
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,411
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	604



	lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	52
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,923
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,853
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86



TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	166
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,016
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,061
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,000
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,966
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	998
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,926
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,060
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	14,861



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,058
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23,329
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	66,779
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	71,046
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,255
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	537
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	416
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	592
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	6,052



	months after initiating ART)	
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,088
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	400
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	688
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,328
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,195
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,162
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,334
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	572
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	416
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of	96



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	592
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,509
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,477
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	399
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	688
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,328
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	12,133



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,551
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,863
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23,974
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,847
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37,095
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,018
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,527
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,002



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39,499
-----------	---	--------

Implementing Mechanism Details

Mechanism ID: 17038	Mechanism Name: Strengthening District Responses for Better HIV/TB Patient Outcomes in eThekweni & Umkhanyakude Districts in KwaZulu-Natal, South Africa	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Maternal, Adolescent and Child Health (MatCH)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 11,510,428	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,510,428	
Funding Source	Funding Amount
GHP-State	11,510,428

Cross-Cutting Budget Attribution(s)

Human Resources for Health	35,000
Food and Nutrition: Policy, Tools, and Service Delivery	37,421
Motor Vehicles: Leased	360,000
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	49,165
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	6,317
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	55,000

Budget Code Information

Mechanism ID: 17038



Mechanism Name: Strengthening District Responses for Better HIV/TB Patient Outcomes in			
Prime Partner Name: eThekweni & Umkhanyakude Districts in KwaZulu-Natal, South Africa			
Maternal, Adolescent and Child Health (MatCH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,044,655	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,408,474	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	257,431	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	514,861	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,027,576	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	257,431	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,168
PMTCT_ART_DSD	New on ART	4,916
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36,490
PMTCT_ART_TA	New on ART	6,994



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,168
PMTCT_STAT_DSD	Number of new ANC and L&D clients	25,422
PMTCT_STAT_DSD	By: Known positives at entry	7,805
PMTCT_STAT_DSD	By: Number of new positives identified	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	7,805
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	754
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	3,012
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	2,456
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	9,823
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	12,288
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	3,764
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2,330
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	9,325
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	11,661
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36,490
PMTCT_STAT_TA	Number of new ANC and L&D clients	36,631
PMTCT_STAT_TA	By: Known positives at entry	11,786
PMTCT_STAT_TA	Sum of Positives Status disaggregates	11,786



PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	1,175
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	4,682
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	3,642
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	14,611
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	18,228
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	5,870
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	3,559
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	14,298
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	18,088
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	361
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	48,498
PP_PREV_DSD	Total number of people in the target population	1,203,346
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,686
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	46,812
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	324,622



HTC_TST_DSD	Age/sex: 10-14 Male	4,183
HTC_TST_DSD	Age/sex: 15-19 Male	10,320
HTC_TST_DSD	Age/sex: 20-24 Male	38,945
HTC_TST_DSD	Age/sex: 25-49 Male	85,887
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	4,573
HTC_TST_DSD	Age/sex: 15-19 Female	18,586
HTC_TST_DSD	Age/sex: 20-24 Female	58,390
HTC_TST_DSD	Age/sex: 25-49 Female	95,377
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	316,261
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	750
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,852
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	6,369
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	13,536
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	788
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	2,987
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	11,529
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	16,776
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,364
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	103,179
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,364
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	158,953
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	16,728
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	262,132
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	278,860



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	515
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	19,408
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	517
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	30,041
HTC_TST_DSD	Test Result by Age: Positive: <1	133
HTC_TST_DSD	Test Result by Age: Positive: 1-9	331
HTC_TST_DSD	Age/sex: <1	6,690
HTC_TST_DSD	Age/sex: 1-9	1,671
HTC_TST_DSD	Service Delivery Point (Community): Other	45,762
HTC_TST_DSD	Service Delivery Point (Facility): VCT	221,741
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	57,119
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	291,739
HTC_TST_TA	Age/sex: 10-14 Male	4,385
HTC_TST_TA	Age/sex: 15-19 Male	10,794
HTC_TST_TA	Age/sex: 20-24 Male	32,386
HTC_TST_TA	Age/sex: 25-49 Male	64,763
HTC_TST_TA	Age/sex: 50+ Male	0
HTC_TST_TA	Age/sex: 10-14 Female	4,387
HTC_TST_TA	Age/sex: 15-19 Female	16,666
HTC_TST_TA	Age/sex: 20-24 Female	49,843
HTC_TST_TA	Age/sex: 25-49 Female	99,763
HTC_TST_TA	Age/sex: 50+ Female	0
HTC_TST_TA	Sum of Age/Sex disaggregates	282,987
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	784
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	1,935
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	5,823
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	11,631



HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	783
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	2,843
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	10,957
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	17,645
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	14
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,752
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	108,160
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,764
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	166,064
HTC_TST_TA	Sum of Aggregated Age/Sex <15	17,516
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	274,224
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	291,740
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	456
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	20,344
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	467
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	31,375
HTC_TST_TA	Test Result by Age: Positive: <1	138
HTC_TST_TA	Test Result by Age: Positive: 1-9	348
HTC_TST_TA	Age/sex: <1	7,002
HTC_TST_TA	Age/sex: 1-9	1,750
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	235,359
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	56,380
TB_STAT_DSD	Number of registered new and relapsed TB cases with	11,753



	documented HIV status, during the reporting period.	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	12,342
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	354
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,348
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	354
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,697
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12,297
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	12,909
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	368
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,549
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	368
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,012
GEND_GBV_DSD	Number of people receiving post-GBV care	810
GEND_GBV_DSD	Age/Sex: 10-14 Female	50
GEND_GBV_DSD	Age/Sex: 20-24 Female	185



GEND_GBV_DSD	Sum of Age/Sex Disaggregates	50
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	405
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	405
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	405
GEND_GBV_DSD	Age/Sex: 15-19 Female	170
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,345
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,039
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	188
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,350
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	188
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,619
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,573
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,297



TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	199
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,434
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	199
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,741
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	221,796
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6,653
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	82,063
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,653
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	126,427
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	229,907
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	6,898
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	85,066
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	6,898
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	131,045
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,893
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,893
PMTCT_EID_TA	By infants who received a virologic test within 2 months	7,106



	of birth	
PMTCT_EID_TA	Sum of Infant Age disaggregates	7,106
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	216,380
TX_CURR_DSD	Age/Sex: 15-19 Male	8,010
TX_CURR_DSD	Age/Sex: 15-19 Female	12,320
TX_CURR_DSD	Sum of age/sex disaggregates	20,330
TX_CURR_DSD	Age/Sex: <1	1,299
TX_CURR_DSD	Age/Sex: <1-9	2,596
TX_CURR_DSD	Age/Sex: 10-14 Male	4,543
TX_CURR_DSD	Age/Sex: 10-14 Female	4,543
TX_CURR_DSD	Age/Sex: 20-24 Male	24,020
TX_CURR_DSD	Age/Sex: 25-49 Male	40,038
TX_CURR_DSD	Age/Sex: 50+ Male	8,010
TX_CURR_DSD	Age/Sex: 20-24 Female	36,994
TX_CURR_DSD	Age/Sex: 25-49 Female	61,671
TX_CURR_DSD	Age/Sex: 50+ Female	12,334
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	215,522
TX_CURR_TA	Age/Sex: 15-19 Male	7,977
TX_CURR_TA	Age/Sex: 15-19 Female	12,266
TX_CURR_TA	Sum of Age/Sex disaggregations	20,243
TX_CURR_TA	Aggregated Age/Sex: <15 Male	85
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,045
TX_CURR_TA	Aggregated Age/Sex: <15 Female	85
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,610
TX_CURR_TA	Sum of Aggregated Age/Sex <15	170
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,655
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,825
TX_CURR_TA	Age/Sex: <1	1,294
TX_CURR_TA	Age/Sex: 1-9	2,598
TX_CURR_TA	Age/Sex: 10-14 Male	4,519



TX_CURR_TA	Age/Sex: 10-14 Female	4,535
TX_CURR_TA	Age/Sex: 20-24 Male	23,923
TX_CURR_TA	Age/Sex: 25-49 Male	39,891
TX_CURR_TA	Age/Sex: 50+ Male	7,977
TX_CURR_TA	Age/Sex: 20-24 Female	36,784
TX_CURR_TA	Age/Sex: 25-49 Female	61,494
TX_CURR_TA	Age/Sex: 50+ Female	12,295
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	62,163
TX_NEW_DSD	By Age/Sex: <1	375
TX_NEW_DSD	By Age/Sex: 1-9	746
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,303
TX_NEW_DSD	By Age/Sex: 15-19 Male	2,302
TX_NEW_DSD	By Age/Sex: 20-24 Male	6,900
TX_NEW_DSD	By Age/Sex: 25-49 Male	11,505
TX_NEW_DSD	By Age/Sex: 50+ Male	2,301
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,307
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,536
TX_NEW_DSD	By Age/Sex: 20-24 Female	10,625
TX_NEW_DSD	By Age/Sex: 25-49 Female	17,718
TX_NEW_DSD	By Age/Sex: 50+ Female	3,545
TX_NEW_DSD	Sum of Age/Sex disaggregates	61,042
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	61,920
TX_NEW_TA	By Age/Sex: 1-9	742
TX_NEW_TA	By Age/Sex: 10-14 Male	1,289
TX_NEW_TA	By Age/Sex: 15-19 Male	2,294



TX_NEW_TA	By Age/Sex: 20-24 Male	6,875
TX_NEW_TA	By Age/Sex: 25-49 Male	11,471
TX_NEW_TA	By Age/Sex: 50+ Male	2,298
TX_NEW_TA	By Age/Sex: 10-14 Female	1,313
TX_NEW_TA	By Age/Sex: 15-19 Female	3,573
TX_NEW_TA	By Age/Sex: 20-24 Female	10,844
TX_NEW_TA	By Age/Sex: 25-49 Female	18,022
TX_NEW_TA	By Age/Sex: 50+ Female	3,603
TX_NEW_TA	Sum of Age/Sex disaggregates	61,582
TX_NEW_TA	Aggregated Grouping by Age: <1	370
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	180,700
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	200,778
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	5,421
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	66,858
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5,421
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	103,000
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	180,267
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	200,297
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	5,404
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	66,704
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	5,404
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	102,755
TX_RET_DSD	Number of adults and children who are still alive and on	122,323



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	130,131
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	734
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,467
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,571
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,528
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,580
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,634
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,528
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,571
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,972
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,920



TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34,846
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,972
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	123,461
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	131,339
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	733
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,475
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,584
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,548
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,621
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,720
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,548
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	2,584



	months after initiating ART)	
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,998
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,987
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34,926
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,998
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	274
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	421

Implementing Mechanism Details

Mechanism ID: 17039	Mechanism Name: Comprehensive Clinic-Based District Services (Hybrid)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Broadreach	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 3,890,131	
Applied Pipeline Amount: 81,084	
Total All Funding Sources and Applied Pipeline Amount: 3,971,215	
Funding Source	Funding Amount
GHP-State	3,890,131

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,025,000
----------------------------	-----------

Budget Code Information

Mechanism ID: 17039			
Mechanism Name: Comprehensive Clinic-Based District Services (Hybrid)			
Prime Partner Name: Broadreach			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	595,682	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	574,598	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	198,561	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	337,122	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,985,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	198,560	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,073
PMTCT_ART_TA	New on ART	154
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	232
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,073
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,116
PMTCT_STAT_TA	By: Known positives at entry	831
PMTCT_STAT_TA	By: Number of new positives identified	1,242
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,073
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	18
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	74
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	111
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	29
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	111
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	168



PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	47
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	191
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	287
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	431
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	170
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	256
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	47
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	188
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	280
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	422
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	55,393
HTC_TST_TA	Age/sex: 10-14 Male	118
HTC_TST_TA	Age/sex: 15-19 Male	1,471
HTC_TST_TA	Age/sex: 20-24 Male	1,764
HTC_TST_TA	Age/sex: 25-49 Male	1,764
HTC_TST_TA	Age/sex: 50+ Male	590
HTC_TST_TA	Age/sex: 10-14 Female	177
HTC_TST_TA	Age/sex: 15-19 Female	2,204



HTC_TST_TA	Age/sex: 20-24 Female	2,648
HTC_TST_TA	Age/sex: 25-49 Female	2,648
HTC_TST_TA	Age/sex: 50+ Female	884
HTC_TST_TA	Sum of Age/Sex disaggregates	14,268
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	6
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	191
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	229
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	230
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	60
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	8
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	287
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	345
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	345
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	86
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,778
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,421
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,061
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,133
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,839
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	48,554
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	55,393
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	333
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,454
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	491
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,678



HTC_TST_TA	Test Result by Age: Positive: <1	0
HTC_TST_TA	Test Result by Age: Positive: 1-9	44
HTC_TST_TA	Age/sex: <1	0
HTC_TST_TA	Age/sex: 1-9	441
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	5,220
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	47,291
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,882
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,586
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,704
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	155
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	879
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	233
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,319
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,369
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,522
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	81
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	466

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	124
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	698
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	67,881
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	4,073
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	23,081
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	6,107
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	34,620
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	1,697
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,528
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	154
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,297
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	77
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	366
PMTCT_EID_TA	Sum of Infant Age disaggregates	366
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	70,625



TX_CURR_TA	Age/Sex: 15-19 Male	1,451
TX_CURR_TA	Age/Sex: 15-19 Female	2,177
TX_CURR_TA	Sum of Age/Sex disaggregations	3,628
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,059
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	11,676
TX_CURR_TA	Aggregated Age/Sex: <15 Female	3,090
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	17,515
TX_CURR_TA	Sum of Aggregated Age/Sex <15	5,149
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	29,191
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	34,340
TX_CURR_TA	Age/Sex: <1	725
TX_CURR_TA	Age/Sex: 1-9	3,629
TX_CURR_TA	Age/Sex: 10-14 Male	1,451
TX_CURR_TA	Age/Sex: 10-14 Female	1,451
TX_CURR_TA	Age/Sex: 20-24 Male	2,902
TX_CURR_TA	Age/Sex: 25-49 Male	6,530
TX_CURR_TA	Age/Sex: 50+ Male	727
TX_CURR_TA	Age/Sex: 20-24 Female	4,355
TX_CURR_TA	Age/Sex: 25-49 Female	9,798
TX_CURR_TA	Age/Sex: 50+ Female	1,089
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,187
TX_NEW_TA	By Age/Sex: 1-9	294
TX_NEW_TA	By Age/Sex: 10-14 Male	118
TX_NEW_TA	By Age/Sex: 15-19 Male	235
TX_NEW_TA	By Age/Sex: 20-24 Male	469
TX_NEW_TA	By Age/Sex: 25-49 Male	1,176
TX_NEW_TA	By Age/Sex: 50+ Male	234
TX_NEW_TA	By Age/Sex: 10-14 Female	118
TX_NEW_TA	By Age/Sex: 15-19 Female	354
TX_NEW_TA	By Age/Sex: 20-24 Female	706
TX_NEW_TA	By Age/Sex: 25-49 Female	1,763



TX_NEW_TA	By Age/Sex: 50+ Female	354
TX_NEW_TA	Sum of Age/Sex disaggregates	5,527
TX_NEW_TA	Aggregated Grouping by Age: <1	60
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	497
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,824
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	747
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	4,238
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	8,306
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	51,113
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	55,334
TX_PVLS_TA	Numerator: Indication: Routine	46,003
TX_PVLS_TA	Numerator: Indication: Targeted	5,110
TX_PVLS_TA	Denominator: Indication: Routine	49,798
TX_PVLS_TA	Denominator: Indication: Targeted	5,536
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	3,067
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	17,376
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	4,598
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	26,072
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	3,318
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	18,812
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	4,977
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	28,227
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	56,466
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	67,846



TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	525
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,624
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,050
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,050
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,099
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,724
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	525
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,050
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,575
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,150
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,087
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12	786



	months after initiating ART)	
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	693
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,468
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,388
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,388
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,775
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,241
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	693



TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,388
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,081
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,163
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,364
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,040
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,811
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,274
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,722
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number	15,414



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,990
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,276
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,985
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16,913

Implementing Mechanism Details

Mechanism ID: 17043	Mechanism Name: Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Reproductive Health& HIV Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17043		
Mechanism Name:	Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth Program		
Prime Partner Name:	Wits Reproductive Health& HIV Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17046	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 6,407,281	
Applied Pipeline Amount: 1,713,385	
Total All Funding Sources and Applied Pipeline Amount: 8,120,666	
Funding Source	Funding Amount
GHP-State	6,407,281

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,781,769
Gender: GBV	232,738
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	386,523
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information



Mechanism ID: 17046			
Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes			
Prime Partner Name: Kheth'Impilo			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,074,408	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	761,792	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	149,726	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	299,451	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,972,179	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	149,725	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status	3,724



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	867
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	119
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,235
PMTCT_ART_TA	New on ART	4,944
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,541
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,724
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,800
PMTCT_STAT_DSD	By: Known positives at entry	714
PMTCT_STAT_DSD	By: Number of new positives identified	450
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,164
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	69
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	105
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	108
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	164
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	9
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	442
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	673



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,162
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	283
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	180
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	8
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	433
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	659
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,140
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,235
PMTCT_STAT_TA	Number of new ANC and L&D clients	59,423
PMTCT_STAT_TA	By: Known positives at entry	7,129
PMTCT_STAT_TA	By: Number of new positives identified	4,263
PMTCT_STAT_TA	Sum of Positives Status disaggregates	11,392
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	3
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	305
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	461
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	2
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	193



PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	294
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	25
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	1,245
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	1,893
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	3,273
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	796
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	514
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	24
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	1,220
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	1,856
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	3,206
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,927
PP_PREV_DSD	Aggregated Age/sex: <15 Female	5,730
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	6,197
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,951
HTC_TST_DSD	Age/sex: 10-14 Male	75



HTC_TST_DSD	Age/sex: 15-19 Male	85
HTC_TST_DSD	Age/sex: 20-24 Male	99
HTC_TST_DSD	Age/sex: 25-49 Male	300
HTC_TST_DSD	Age/sex: 50+ Male	105
HTC_TST_DSD	Age/sex: 10-14 Female	73
HTC_TST_DSD	Age/sex: 15-19 Female	87
HTC_TST_DSD	Age/sex: 20-24 Female	100
HTC_TST_DSD	Age/sex: 25-49 Female	326
HTC_TST_DSD	Age/sex: 50+ Female	161
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,411
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	17
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	60
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	11
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	17
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	65
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	18
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,171
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,734
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	594
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,452
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,765
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,186
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,951
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	17



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	237
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	209
HTC_TST_DSD	Test Result by Age: Positive: <1	1
HTC_TST_DSD	Test Result by Age: Positive: 1-9	10
HTC_TST_DSD	Age/sex: <1	67
HTC_TST_DSD	Age/sex: 1-9	243
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,754
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	4,431
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	767
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	52,250
HTC_TST_TA	Age/sex: 10-14 Male	280
HTC_TST_TA	Age/sex: 15-19 Male	319
HTC_TST_TA	Age/sex: 20-24 Male	370
HTC_TST_TA	Age/sex: 25-49 Male	1,123
HTC_TST_TA	Age/sex: 50+ Male	397
HTC_TST_TA	Age/sex: 10-14 Female	272
HTC_TST_TA	Age/sex: 15-19 Female	325
HTC_TST_TA	Age/sex: 20-24 Female	374
HTC_TST_TA	Age/sex: 25-49 Female	1,221
HTC_TST_TA	Age/sex: 50+ Female	606
HTC_TST_TA	Sum of Age/Sex disaggregates	5,287
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	10
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	64
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	75
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	225



HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	42
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	10
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	64
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	76
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	242
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	65
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,694
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,991
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,900
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,665
HTC_TST_TA	Sum of Aggregated Age/Sex <15	12,594
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	39,656
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	52,250
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	119
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,570
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	65
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,220
HTC_TST_TA	Test Result by Age: Positive: <1	3
HTC_TST_TA	Test Result by Age: Positive: 1-9	36
HTC_TST_TA	Age/sex: <1	250
HTC_TST_TA	Age/sex: 1-9	911
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	12,431
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	154
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	33,794
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	6,080



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,883
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,025
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	519
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,173
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	206
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	983
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	21,949
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	23,025
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,951
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,942
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,574
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,484
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,558



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,725
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	272
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	615
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	135
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	536
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	11,865
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	13,126
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,868
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,292
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	1,541

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,226
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	30,280
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,450
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	12,182
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,275
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	10,372
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	178,180
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	32,070
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	71,875
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	13,255
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	60,978
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	971
PMTCT_EID_DSD	Sum of Infant Age disaggregates	971
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_TA	By infants who received a virologic test within 2 months	7,491

	of birth	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	7,491
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	63
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,512
TX_CURR_DSD	Age/Sex: 15-19 Male	725
TX_CURR_DSD	Age/Sex: 15-19 Female	743
TX_CURR_DSD	Sum of age/sex disaggregates	1,468
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,173
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,332
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,191
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	11,816
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8,364
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	24,148
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	32,512
TX_CURR_DSD	Age/Sex: <1	566
TX_CURR_DSD	Age/Sex: <1-9	2,068
TX_CURR_DSD	Age/Sex: 10-14 Male	639
TX_CURR_DSD	Age/Sex: 10-14 Female	622
TX_CURR_DSD	Age/Sex: 20-24 Male	845
TX_CURR_DSD	Age/Sex: 25-49 Male	2,549
TX_CURR_DSD	Age/Sex: 50+ Male	884
TX_CURR_DSD	Age/Sex: 20-24 Female	851
TX_CURR_DSD	Age/Sex: 25-49 Female	2,773
TX_CURR_DSD	Age/Sex: 50+ Female	1,372
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	195,260



TX_CURR_TA	Age/Sex: 15-19 Male	3,633
TX_CURR_TA	Age/Sex: 15-19 Female	3,719
TX_CURR_TA	Sum of Age/Sex disaggregations	7,352
TX_CURR_TA	Aggregated Age/Sex: <15 Male	31,450
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	74,284
TX_CURR_TA	Aggregated Age/Sex: <15 Female	17,954
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	69,316
TX_CURR_TA	Sum of Aggregated Age/Sex <15	49,404
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	143,600
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	193,004
TX_CURR_TA	Age/Sex: <1	2,835
TX_CURR_TA	Age/Sex: 1-9	10,358
TX_CURR_TA	Age/Sex: 10-14 Male	3,200
TX_CURR_TA	Age/Sex: 10-14 Female	3,116
TX_CURR_TA	Age/Sex: 20-24 Male	4,231
TX_CURR_TA	Age/Sex: 25-49 Male	12,767
TX_CURR_TA	Age/Sex: 50+ Male	4,425
TX_CURR_TA	Age/Sex: 20-24 Female	4,265
TX_CURR_TA	Age/Sex: 25-49 Female	13,885
TX_CURR_TA	Age/Sex: 50+ Female	6,872
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,497
TX_NEW_DSD	By Age/Sex: <1	40
TX_NEW_DSD	By Age/Sex: 1-9	145
TX_NEW_DSD	By Age/Sex: 10-14 Male	45
TX_NEW_DSD	By Age/Sex: 15-19 Male	51
TX_NEW_DSD	By Age/Sex: 20-24 Male	59
TX_NEW_DSD	By Age/Sex: 25-49 Male	179
TX_NEW_DSD	By Age/Sex: 50+ Male	60
TX_NEW_DSD	By Age/Sex: 10-14 Female	44
TX_NEW_DSD	By Age/Sex: 15-19 Female	52
TX_NEW_DSD	By Age/Sex: 20-24 Female	60



TX_NEW_DSD	By Age/Sex: 25-49 Female	194
TX_NEW_DSD	By Age/Sex: 50+ Female	96
TX_NEW_DSD	Sum of Age/Sex disaggregates	840
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	402
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	952
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	239
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	904
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,497
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,802
TX_NEW_TA	By Age/Sex: 1-9	599
TX_NEW_TA	By Age/Sex: 10-14 Male	183
TX_NEW_TA	By Age/Sex: 15-19 Male	210
TX_NEW_TA	By Age/Sex: 20-24 Male	246
TX_NEW_TA	By Age/Sex: 25-49 Male	745
TX_NEW_TA	By Age/Sex: 50+ Male	262
TX_NEW_TA	By Age/Sex: 10-14 Female	179
TX_NEW_TA	By Age/Sex: 15-19 Female	215
TX_NEW_TA	By Age/Sex: 20-24 Female	246
TX_NEW_TA	By Age/Sex: 25-49 Female	804
TX_NEW_TA	By Age/Sex: 50+ Female	397
TX_NEW_TA	Sum of Age/Sex disaggregates	3,487
TX_NEW_TA	Aggregated Grouping by Age: <1	164
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	2,055
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	4,925
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1,146
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	4,527
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	12,653
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,335



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,261
TX_PVLS_DSD	Numerator: Indication: Routine	26,335
TX_PVLS_DSD	Denominator: Indication: Routine	13,215
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	4,741
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	10,621
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,961
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,013
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,267
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	11,799
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,180
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	10,015
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	158,161
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	175,741
TX_PVLS_TA	Numerator: Indication: Routine	146,466
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	121,601
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	28,469
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	63,959
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	11,662
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	54,068
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	31,524
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	70,835
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	13,293
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	60,381
TX_RET_DSD	Number of adults and children who are still alive and on	26,034



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	27,695
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	357
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,304
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	403
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	457
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	533
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,608
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	557
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	392
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	469
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	537



TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,749
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	865
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	380
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,388
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	429
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	487
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	567
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,710



TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	592
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	417
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	498
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	571
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,860
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	921
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,273
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,080



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,400
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,333
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,530
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,685
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,553
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,927
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	160,870
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	171,132
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,790



TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,534
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,018
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,291
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,669
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,051
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,789
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,963
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,346
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,689
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,759
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,333
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	1,900



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,949
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,148
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,438
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,840
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,565
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,969
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	2,091



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,495
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,859
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,317
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,611
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26,827
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62,809
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,151
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57,106
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total	27,676



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64,885
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,729
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59,139

Implementing Mechanism Details

Mechanism ID: 17452	Mechanism Name: AIHA Twinning Capacity Building (HRSA)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 750,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 750,000	
Funding Source	Funding Amount
GHP-State	750,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	700,000
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	20,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	20,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers

Budget Code Information

Mechanism ID:	17452		
Mechanism Name:	AIHA Twinning Capacity Building (HRSA)		
Prime Partner Name:	American International Health Alliance		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	750,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	282
HRH_PRE	By Graduates: Other	282
HRH_PRE	Sum of Graduates disaggreagtes	282

Implementing Mechanism Details

Mechanism ID: 17459	Mechanism Name: HSRC (CDC GH001629)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Human Sciences Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,950,000	
Total All Funding Sources and Applied Pipeline Amount: 1,950,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 17459			
Mechanism Name: HSRC (CDC GH001629)			
Prime Partner Name: Human Sciences Research Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17493	Mechanism Name: NHLS (CDC GH001631)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Health Laboratory Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 320,608	
Applied Pipeline Amount: 3,286,944	
Total All Funding Sources and Applied Pipeline Amount: 3,607,552	
Funding Source	Funding Amount
GHP-State	320,608

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	66,847
---------------------------	--------

Budget Code Information



Mechanism ID: 17493			
Mechanism Name: NHLS (CDC GH001631)			
Prime Partner Name: National Health Laboratory Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	220,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	0
LAB_PT_TA	CD4: Number of laboratories that perform this testing	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	984
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,969
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories	0



	that perform this testing	
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

Implementing Mechanism Details

Mechanism ID: 17505	Mechanism Name: UNICEF (CDC PS002027)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	160,000
Gender: Gender Equality	1,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID:	17505		
Mechanism Name:	UNICEF (CDC PS002027)		
Prime Partner Name:	United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	80,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17506	Mechanism Name: Beyond Zero Advanced Clinical Care Centres (CDC GH001143)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Beyond Zero	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 371,003	
Applied Pipeline Amount: 1,328,997	
Total All Funding Sources and Applied Pipeline Amount: 1,700,000	
Funding Source	Funding Amount
GHP-State	371,003

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
----------------------------	---------



Budget Code Information

Mechanism ID: 17506			
Mechanism Name: Beyond Zero Advanced Clinical Care Centres (CDC GH001143)			
Prime Partner Name: Beyond Zero			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	291,003	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17507	Mechanism Name: Kheth'Impilo Advanced Clinical Care Centres (CDC GH001145)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 989,614	
Applied Pipeline Amount: 1,610,386	
Total All Funding Sources and Applied Pipeline Amount: 2,600,000	
Funding Source	Funding Amount
GHP-State	989,614

Cross-Cutting Budget Attribution(s)

Human Resources for Health	900,000
Motor Vehicles: Purchased	74,800

Budget Code Information

Mechanism ID: 17507			
Mechanism Name: Kheth"Impilo Advanced Clinical Care Centres (CDC GH001145)			
Prime Partner Name: Kheth'Impilo			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	62,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	212,114	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	62,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	652,500	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15
PMTCT_ART_TA	New on ART	4
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	4
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15
PMTCT_STAT_TA	Number of new ANC and L&D clients	15
PMTCT_STAT_TA	By: Known positives at entry	2
PMTCT_STAT_TA	By: Number of new positives identified	1
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,168
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	210
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	479
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	82
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	397
HTC_TST_TA	Sum of Aggregated Age/Sex <15	292
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	876
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,168
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+	29



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	20
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	292
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	724
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	152
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	14
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	15
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	14
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	15
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3



TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	530
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	95
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	217
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	37
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	180
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	649
TX_CURR_TA	Aggregated Age/Sex: <15 Male	117
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	266
TX_CURR_TA	Aggregated Age/Sex: <15 Female	45
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	221
TX_CURR_TA	Sum of Aggregated Age/Sex <15	162
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	487
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	649
TX_NEW_TA	Number of adults and children newly enrolled on	57



	antiretroviral therapy (ART)	
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	10
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	23
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	4
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	19
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	56
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	526
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	584
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	95
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	216
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	37
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	179
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	105
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	239
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	41
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	199
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	591
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	628
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	242
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number	41



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	201
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	113
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	258
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	214

Implementing Mechanism Details

Mechanism ID: 17510	Mechanism Name: Technical Assistance (TA) Indicators
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Macro Atlanta	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17510		
Mechanism Name:	Technical Assistance (TA) Indicators		
Prime Partner Name:	Macro Atlanta		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17512	Mechanism Name: WHO HIV Prevention (CDC GH001180)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 584,860	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 584,860	
Funding Source	Funding Amount
GHP-State	584,860

Cross-Cutting Budget Attribution(s)

Condom programming	1,500
Gender: GBV	6,750
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Human Resources for Health	6,750
Key Populations: FSW	8,100
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	8,100
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Gender: Gender Equality	6,750
Focus Area:	Promoting gender-related policies and laws that increase legal protection



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Water	25,000

Budget Code Information

Mechanism ID: 17512			
Mechanism Name: WHO HIV Prevention (CDC GH001180)			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	14,426	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	70,434	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	45,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17533	Mechanism Name: SA Partners Care and Support (CDC GH001554)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,004,426	
Applied Pipeline Amount: 2,495,574	
Total All Funding Sources and Applied Pipeline Amount: 3,500,000	
Funding Source	Funding Amount
GHP-State	1,004,426



Cross-Cutting Budget Attribution(s)

Human Resources for Health	900,000
Gender: GBV	25,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Key Populations: FSW	175,000
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Key Populations: MSM and TG	175,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners

Budget Code Information

Mechanism ID:	17533		
Mechanism Name:	SA Partners Care and Support (CDC GH001554)		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	451,991	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	150,664	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,885	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17536	Mechanism Name: Accelerating Strategies for Practical Innovation & Research in Economic Strengthening (ASPIRES)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,000,000	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID:	17536		
Mechanism Name:	Accelerating Strategies for Practical Innovation & Research in		
Prime Partner Name:	Economic Strengthening (ASPIRES)		
	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17537	Mechanism Name: Strategic, Evidence-Based Communication Interventions Systematically Applied at Multiple Levels for Greater Effectiveness of HIV Prevention Programs
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins Health and Education in South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,448,669	
Applied Pipeline Amount: 851,331	
Total All Funding Sources and Applied Pipeline Amount: 6,300,000	
Funding Source	Funding Amount
GHP-State	5,448,669



Cross-Cutting Budget Attribution(s)

Condom programming	3,000,000
Gender: GBV	1,000,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17537		
Mechanism Name:	Strategic, Evidence-Based Communication Interventions Systematically Applied at Multiple Levels for Greater Effectiveness of HIV Prevention		
Prime Partner Name:	Programs Johns Hopkins Health and Education in South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	448,669	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	148,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	852,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	4,000,000	0
-----------	------	-----------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17538	Mechanism Name: Community-Based Comprehensive HIV Prevention, Counseling and testing Program to Reduce HIV Incidence
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins Health and Education in South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 5,766,295	
Total All Funding Sources and Applied Pipeline Amount: 5,766,295	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17538
Mechanism Name:	Community-Based Comprehensive HIV Prevention, Counseling and testing Program to Reduce HIV Incidence
Prime Partner Name:	Johns Hopkins Health and Education in South Africa



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	461,471
PP_PREV_DSD	Total number of people in the target population	1,205,615
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	340,338
PP_PREV_DSD	Aggregated Age/sex: <15 Female	6,901
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	114,233
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	38,079
HTC_TST_DSD	Age/sex: 15-19 Male	1,298
HTC_TST_DSD	Age/sex: 20-24 Male	5,784
HTC_TST_DSD	Age/sex: 25-49 Male	15,210
HTC_TST_DSD	Age/sex: 10-14 Female	1,073



HTC_TST_DSD	Age/sex: 15-19 Female	5,182
HTC_TST_DSD	Age/sex: 20-24 Female	8,134
HTC_TST_DSD	Age/sex: 25-49 Female	1,398
HTC_TST_DSD	Sum of Age/Sex disaggregates	38,079
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	130
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	580
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,521
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	107
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	517
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	813
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	140
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,293
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,073
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,713
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,073
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	37,006
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	38,079
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,232
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	107
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,469
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	7,617
HTC_TST_DSD	Service Delivery Point (Community): Other	30,462

Implementing Mechanism Details

Mechanism ID: 17767	Mechanism Name: Broadreach (CDC GH001202)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Broadreach	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 200,000	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17767			
Mechanism Name: Broadreach (CDC GH001202)			
Prime Partner Name: Broadreach			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17768	Mechanism Name: Columbia University Nimart Evaluation (CDC GH001194)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 57,784	
Applied Pipeline Amount: 542,216	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount
GHP-State	57,784

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Budget Code Information

Mechanism ID:	17768		
Mechanism Name:	Columbia University Nimart Evaluation (CDC GH001194)		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	57,784	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17769	Mechanism Name: University of Washington Capacity Building for Systems Strengthening CDC GH001197)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,625,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,625,000	
Funding Source	Funding Amount
GHP-State	5,625,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	25,000
Gender: GBV	2,500
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Condom programming	11,250
Gender: Gender Equality	2,500
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	17769		
Mechanism Name:	University of Washington Capacity Building for Systems Strengthening (CDC GH001197)		
Prime Partner Name:	University of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	855,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	25,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	124,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,010,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17790	Mechanism Name: Comprehensive VMMC Training Programs/Ongoing Mentoring and Private Sector VMMC Training and Mentoring
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: The Centre for HIV and AIDS Prevention Studies	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 170,360	
Applied Pipeline Amount: 429,640	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount
GHP-State	170,360

Cross-Cutting Budget Attribution(s)

Condom procurement	50,000
Motor Vehicles: Purchased	20,000

Budget Code Information

Mechanism ID:	17790		
Mechanism Name:	Comprehensive VMMC Training Programs/Ongoing Mentoring and Private Sector VMMC Training and Mentoring		
Prime Partner Name:	The Centre for HIV and AIDS Prevention Studies		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	170,360	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17791	Mechanism Name: Catalyzing an Adolescent Combination Prevention Program in South Africa (Activity 1), & Community SKILLZ for Health: Scaling-up Soccer-Based HIV and SGBV Prevention Programmes for Adolescents through Partnerships in South Africa (Activity 2)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Grassroots Soccer		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17791
Mechanism Name:	Catalyzing an Adolescent Combination Prevention Program in South Africa (Activity 1), & Community SKILLZ for Health: Scaling-up
Prime Partner Name:	Africa (Activity 1), & Community SKILLZ for Health: Scaling-up



Soccer-Based HIV and SGBV Prevention Programmes for Adolescents through Partnerships in South Africa (Activity 2) Grassroots Soccer			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17801	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 281,939	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 281,939	
Funding Source	Funding Amount
GHP-State	281,939

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Budget Code Information



Mechanism ID: 17801			
Mechanism Name: MEASURE Evaluation Phase IV			
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	90,582	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	191,357	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17968	Mechanism Name: Wits Health Consortium Capacity Building (CDC GH001538)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Health Consortium, Reproductive Health Research Unit	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 511,555	
Applied Pipeline Amount: 488,445	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	511,555

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Human Resources for Health	360,000
Condom programming	3,750



Budget Code Information

Mechanism ID: 17968			
Mechanism Name: Wits Health Consortium Capacity Building (CDC GH001538)			
Prime Partner Name: Wits Health Consortium, Reproductive Health Research Unit			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	151,555	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	216,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	72,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	27,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
GEND_GB_V_DSD	Number of people receiving post-GBV care	1,300



Implementing Mechanism Details

Mechanism ID: 17969	Mechanism Name: SURMEPI: Stellenbosch University Rural Medical Education Partenreship Initiative HQ T84HA21652
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Stellenbosch, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17969		
Mechanism Name:	SURMEPI: Stellenbosch University Rural Medical Education		
Prime Partner Name:	Partenreship Initiative HQ T84HA21652 University of Stellenbosch, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17980	Mechanism Name: Masibambisane1
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: South African Military Health Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 66,673	
Total All Funding Sources and Applied Pipeline Amount: 66,673	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17980			
Mechanism Name: Masibambisane1			
Prime Partner Name: South African Military Health Service			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17981	Mechanism Name: Society For Family Health/Population Services International
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Society for Family Health - South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 17981			
Mechanism Name: Society For Family Health/Population Services International			
Prime Partner Name: Society for Family Health - South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0

Implementing Mechanism Details

Mechanism ID: 18021	Mechanism Name: Health Information Systems Programs (CDC GH001922)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Information Systems Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,493,862	
Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 2,893,862	
Funding Source	Funding Amount

Approved



GHP-State	2,493,862
-----------	-----------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18021		
Mechanism Name:	Health Information Systems Programs (CDC GH001922)		
Prime Partner Name:	Health Information Systems Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,498,354	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	995,508	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18022	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18023	TBD: Yes
----------------------------	----------



REDACTED

Implementing Mechanism Details

Mechanism ID: 18083	Mechanism Name: Council for Scientific and Industrial Research (CDC GH001937)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Budget Code Information

Mechanism ID:	18083		
Mechanism Name:	Council for Scientific and Industrial Research (CDC GH001937)		
Prime Partner Name:	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	500,000	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18231	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18254	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18298	Mechanism Name: Health Finance and Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18298			
Mechanism Name: Health Finance and Governance			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18299	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18300	Mechanism Name: HRH2030
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
----------------------------	---------

Budget Code Information

Mechanism ID:	18300		
Mechanism Name:	HRH2030		
Prime Partner Name:	Chemonics International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	350,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18307	Mechanism Name: UCFS (GH000977 - Central Mech)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UCSF CDC HQ	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount



GHP-State	400,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18307			
Mechanism Name: UCFS (GH000977 - Central Mech)			
Prime Partner Name: UCSF CDC HQ			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18313	Mechanism Name: UNAIDS (CDC GH001971)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount

Approved



GHP-State	300,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18313		
Mechanism Name:	UNAIDS (CDC GH001971)		
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18314	Mechanism Name: NASTAD (GH001508 - Central Mech)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 450,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 450,000	



Funding Source	Funding Amount
GHP-State	450,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18314			
Mechanism Name: NASTAD (GH001508 - Central Mech)			
Prime Partner Name: National Alliance of State and Territorial AIDS Directors			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	450,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18321	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Inter-Agency Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 3,607,311	
Applied Pipeline Amount: 7,032,203	



Total All Funding Sources and Applied Pipeline Amount: 10,639,514	
Funding Source	Funding Amount
GHP-State	3,607,311

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

Budget Code Information

Mechanism ID:	18321		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,007,311	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18480	Mechanism Name: Foundation for Professional Development Comprehensive (CDC GH001932)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Professional Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



G2G: No	Managing Agency:
Total All Funding Sources: 40,163,484	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 40,163,484	
Funding Source	Funding Amount
GHP-State	40,163,484

Cross-Cutting Budget Attribution(s)

Gender: GBV	829,927
Gender: Gender Equality	829,927

Budget Code Information

Mechanism ID:	18480		
Mechanism Name:	Foundation for Professional Development Comprehensive (CDC GH001932)		
Prime Partner Name:	Foundation for Professional Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	1,544,738	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	12,385,365	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	26,233,381	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18481	Mechanism Name: Health Systems Trust Comprehensive (CDC GH001980)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Systems Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 4,917,835	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,917,835	
Funding Source	Funding Amount
GHP-State	4,917,835

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,336,098
----------------------------	-----------

Budget Code Information

Mechanism ID:	18481		
Mechanism Name:	Health Systems Trust Comprehensive (CDC GH001980)		
Prime Partner Name:	Health Systems Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,455,121	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	70,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	3,392,714	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18482	Mechanism Name: TB/HIV Care Comprehensive (CDC GH001933)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TB/HIV Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 6,513,431	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,513,431	
Funding Source	Funding Amount
GHP-State	6,513,431

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	1,182,181
----------------------	-----------

Budget Code Information

Mechanism ID: 18482
Mechanism Name: TB/HIV Care Comprehensive (CDC GH001933)



Prime Partner Name: TB/HIV Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	6,513,431	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18483	Mechanism Name: MATCH (Wits Health Consortium) (CDC GH001934)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Wits Health Consortium (Pty) Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 3,392,908	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,392,908	
Funding Source	Funding Amount
GHP-State	3,392,908

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,182,181
-----------------------------	-----------

Budget Code Information

Mechanism ID: 18483



Mechanism Name:	MATCH (Wits Health Consortium) (CDC GH001934)		
Prime Partner Name:	Wits Health Consortium (Pty) Limited		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,696,455	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,696,453	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18484	Mechanism Name: Aurum Comprehensive (CDC GH001981)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Aurum Health Research	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 11,070,929	
Applied Pipeline Amount: 23,352,170	
Total All Funding Sources and Applied Pipeline Amount: 34,423,099	
Funding Source	Funding Amount
GHP-State	11,070,929

Cross-Cutting Budget Attribution(s)

Condom procurement	152,780
Condom programming	829,927



Budget Code Information

Mechanism ID: 18484			
Mechanism Name: Aurum Comprehensive (CDC GH001981)			
Prime Partner Name: Aurum Health Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	7,899,327	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,914,701	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,256,901	0

Implementing Mechanism Indicator Information

(No data provided.)

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		0	0	0
Computers/IT Services		347,586		0	347,586	347,586



ICASS		438,500		0	438,500	438,500
Indirect Costs		0		0	0	0
Institutional Contractors		1,773,423	0	0	1,773,423	1,773,423
Management Meetings/Professional Development		526,834		0	526,834	526,834
Non-ICASS Administrative Costs		1,274,847		0	1,274,847	1,274,847
Peace Corps Volunteer Costs		81,420	0	0	81,420	81,420
Staff Program Travel		292,872	0	0	292,872	292,872
USG Staff Salaries and Benefits - Internationally Recruited		3,078,260	0	0	3,078,260	3,078,260
USG Staff Salaries and Benefits - Locally Recruited		3,531,211	0	0	3,531,211	3,531,211
Total	0	11,344,953	0	0	11,344,953	11,344,953

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories
-------------------------------	-----	-----------	-----------	------------------	-------	---



						and Applied Pipeline Amount
Computers/IT Services		0		13,979	0	13,979
ICASS		0		58,194	0	58,194
Indirect Costs		0		41,936	0	41,936
Staff Program Travel		0		27,755	0	27,755
USG Staff Salaries and Benefits - Locally Recruited		0		127,331	0	127,331
Total	0	0	0	269,195	0	269,195

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing	1,991,468			0	1,991,468	1,991,468
Computers/IT Services	853,820			0	853,820	853,820
ICASS	604,712	0		1,081,518	604,712	1,686,230
Indirect Costs		0		1,676,112	0	1,676,112
Institutional		0		396,256	0	396,256



Contractors						
Management Meetings/Professional Development		0		309,904	0	309,904
Non-ICASS Administrative Costs		0		774,034	0	774,034
Non-ICASS Motor Vehicles		0		30,000	0	30,000
Staff Program Travel		0		1,173,147	0	1,173,147
USG Staff Salaries and Benefits				0	0	0
USG Staff Salaries and Benefits - Internationally Recruited		0		2,354,784	0	2,354,784
USG Staff Salaries and Benefits - Locally Recruited		0		4,631,423	0	4,631,423
Total	3,450,000	0	0	12,427,178	3,450,000	15,877,178

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories
-------------------------------	-----	-----------	-----------	------------------	-------	---



						and Applied Pipeline Amount
ICASS		502,522		0	502,522	502,522
Institutional Contractors				0	0	0
Management Meetings/Professional Development		356,000		0	356,000	356,000
Non-ICASS Administrative Costs		48,000		0	48,000	48,000
Peace Corps Volunteer Costs		25,000		0	25,000	25,000
Staff Program Travel		270,493		0	270,493	270,493
USG Staff Salaries and Benefits - Internationally Recruited		137,350		0	137,350	137,350
USG Staff Salaries and Benefits - Locally Recruited		298,754		1,276,709	298,754	1,575,463
Total	0	1,638,119	0	1,276,709	1,638,119	2,914,828

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing



						Business Categories and Applied Pipeline Amount
Computers/IT Services		1,500		0	1,500	1,500
Indirect Costs		195,000		0	195,000	195,000
Institutional Contractors		26,000		0	26,000	26,000
Management Meetings/Professional Development		14,000		0	14,000	14,000
Peace Corps Volunteer Costs		741,000		400,000	741,000	1,141,000
Staff Program Travel		52,000		0	52,000	52,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		520,500		0	520,500	520,500
Total	0	1,550,000	0	400,000	1,550,000	1,950,000